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I. Introduction 
I.1. Cardiovascular Diseases and Myocardial Infarction 
Cardiovascular diseases (CVD) are a group of malfunctions of the heart and blood 
vessels which are causing the highest number of death world wide. Annually there 
are more people dying from CVD than from any other disease group. Statistics 
published by the World Health Organisation 1 state that approximately 17.1 million 
people died from CVD in 2004, which is representing 29% of all death globally. Of the 
CVD casualities, 50% were caused by coronary heart disease (CHD). Myocardial 
infarction is usually an acute event and is mostly caused by a blockade, thrombus, 
which impedes the blood flow to the heart. Atherosclerosis, the build up of fatty 
deposits on the inner arterial wall, is the most common reason for this pathology. In 
low- and middle income countries, the risk of developing CVDs is disproportionally 
high as they are more exposed to risk factors. 82% of the total deaths due to CVDs 
take place in these countries. Of course healthy diet, regular physical activities and 
avoiding tobacco smoke improve significantly the prognosis of CVDs. However, there 
is an urgent need for new medications treating acute cardiovascular diseases like 
myocardial infarction and ischemic stroke. Therefore, it is very important for the future 
to investigate the underlying mechanisms of these pathologies and to devise new 
therapeutical treatments to prevent and cure CVDs 1. 
The heart is the restless motor of our life cycle. Regrettably, acute myocardial 
infarction is one of the leading causes of mortality and morbidity worldwide. However, 
the survival rate of patients hospitalized in the United States suffering from 
myocardial infarction constitutes 95%. This delineates a notable improvement in 
survival and is mainly caused by an improved emergency medical response and 
improved treatment strategies. Notwithstanding, the complications after myocardial 
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infarction increase with age and risk factor exposure. There have been many major 
risk factors identified which correlate with the development of myocardial infarction. 
These are hyperlipidemia, diabetes mellitus, hypertension, tobacco use, male gender 
and family history of atherosclerotic arterial diseases 2-4. In general, myocardial 
infarction arises when myocardial ischemia, an abated blood supply to the heart, 
exceeds a particular threshold and overcomes the repair mechanism of myocardial 
cells which is designed to preserve normal operating function and homeostasis. If 
ischemia at this critical time point lasts for a longer period of time, an irreversible 
myocardial cell damage or even cell death will occur 4 (Figure 1). The reasons for 
critical myocardial ischemia can either be an increased myocardial metabolic 
demand, a decreased delivery of oxygen and nutrients to the myocardium through 
the coronary circulation or a combination of both. The oxygen and nutrient supply of 
the myocardium is obstructed when a thrombus caps atherosclerotic plaque which 
further occludes coronaries 2. 
 
Figure 1 Scheme indicating heart muscle damage after arterial occlusion. A plaque buildup in a coronary 
artery can lead to blocked blood flow resulting in tissue ischemia and dead heart muscle. 
5
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I.2. Underlying Pathogeneses of Myocardial Infarction 
I.2.1. Atherosclerosis 
The primary initial steps in atherosclerosis (Figure 2) are the increase of endothelial 
permeability to lipoproteins, which is mediated by nitric oxide, prostacyclin, platelet-
derived growth factor, angiotensin II 6, and consecutive adhesion of platelets and 
leukocytes. This is caused by an endothelial cell-dysfunction due to an activation of 
pro-inflammatory mechanisms by hyperlipidemia. Monocytes are recruited into the 
vessel wall leading to a local accumulation of lipids, formation of fatty streaks and 
their transformation into foam cells. The fibroproliferative progression of the plaque 
increases because of continued mononuclear cell-influx, deposition of matrix 
components and recruitment of smooth muscle cells 7 creating a necrotic core and a 
fibrous cap that walls off the lesion from the lumen. The fibrous cap is covered by a 
mixture of leukocytes, lipids, and debris which then may form a necrotic core. Due to 
additional leukocyte adhesion and their entry, expands the lesion at their shoulders 6. 
The thinning and erosion of the fibrous cap eventually destabilizes the entire plaque 
leading to plaque rupture 7. The thinning of the fibrous cap is apparently due to a 
continuous influx and activation of macrophages which is accompanied by an 
enzyme release by macrophages which leads to matrix degradation and the rupture 
of the plaque 6. Plaque rupture is accompanied by the activation of the coagulation 
system and thrombosis in the artery, and is responsible of the desastrous 
complications of atherosclerosis, like myocardial infarction or stroke. It is generally 
accepted that all event cascades which lead to initiation and progression of 
atherosclerosis are controlled and modulated by chemokines 8, 9. 
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Figure 2 Scheme on the inflammatory development of atherosclerosis. The first changes preceding the 
formation of lesions of atherosclersosis take place in the endothelium, characterized by endothelial permeability 
to e.g. lipoproteins. In the next step, fatty streaks are formed, thus leading to intermediate and advanced lesions. 
A rupture of the fibrous plaque can then lead to thrombosis and myocardial complications. 
6
 
I.2.2. Thrombosis 
After a vascular damage it is necessary to maintain an upright closed, high-pressure 
circulatory system, i.e. to maintain haemostasis. Expeditiously after a vessel-wall 
injury and the extravasation of blood from the circulation, events in the vessel wall 
and blood are initiated to seal the lesion. In a first step circulating platelets are 
recruited to the site of injury, where they are primary elements of thrombus formation. 
Additionally, blood coagulation, initiated by tissue factors, provokes the formation of 
thrombin and fibrin. Under normal circumstances, these processes take place 
accompanying and under regular conditions to form thrombi temporally and spatially. 
But when pathological conditions of the vessel affect the regulatory mechanisms of 
haemostasis, thrombosis can be initiated due to an excessive production of thrombin. 
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Thrombosis is a crucial event in arterial diseases and can be followed by myocardial 
infarction or stroke 10. 
I.3. Molecular Mechanisms 
I.3.1. Chemokines and Chemokine Receptors 
Chemokines are a superfamily of small (8-10 kDa) chemotactic cytokines, which 
have principally been associated with inflammation due to their role in the control of 
leukocyte migration. Up to now, there are approximately 50 human chemokines 
known which have the ability to interact with about 20 different chemokine receptors 
expressed on different subsets of leukocytes. They are divided into subfamilies 
according to the number and position of the first two cysteine residues (CC, CXC, 
CX3C, XC). The CC chemokines, so named because the first two of the four cysteine 
residues in these molecules are adjacent to each other, constitute the largest 
chemokine family and are active in vivo supposedly as dimers, tetramers or even 
higher-order multimers. They are involved in mononuclear cell attraction to the sites 
of trauma, bacterial and mycobacterial infection, toxin exposure, ischemia and 
inflammation 9, 11, 12. The most thoroughly characterized CC chemokine is monocyte 
chemoattractant protein 1 (MCP-1). It is a potent agonist for monocytes, dendritic 
cells, memory T cells, and basophils11. 
Secondly, the family of CXC chemokines, which have a single amino acid residue 
located between the first two cysteine residues, participates in the regulation of 
polymorphonuclear leukocyte attraction to inflamed tissue 9, 11, 13. A subfamily of the 
CXC chemmokines has a characteristic ELR motif near the N terminal of the 
molecule 14. This subtype attracts neutrophils and contributes to wound healing. A 
prominent example is CXCL8 (interleukine-8), designated as ELR+, which attracts 
polymorphonuclear leukocytes to sites of acute inflammation and also activates 
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monocytes and may direct the recruitment of these cells to vascular lesions 13, 15. It is 
further clear that ELR+ CXC chemokines orchestrate the early phase of wound 
healing 16 and that ELR- and ELR+ CXC chemokines are closely linked to 
angiogenesis 17. 
There are two more chemokines which show up special characteristics due to their 
number and position of the cysteine residues. 
First the CX3C family, of which fractalkine (CX3CL1) is the only member 
18, 19. The 
chemokine domain of CX3CL1 is fused to a mucin-like stalk and transmembrane and 
cytoplasmic regions, thereby forming a cell-adhesion receptor capable of arresting 
cells under physiologic flow conditions 20, 21. The enzyme tumor necrosis factor 
(TNF)-α–converting enzyme, can cleave CX3CL1 from the cell membrane, freeing the 
cytokine to function as a soluble chemoattractant 22, 23. 
Secondly, the C chemokine, of which lymphotactin is the only member. Lymphotactin 
is similar to members of both the CC and CXC chemokine families but lacks two of 
the four cysteine residues that are characteristics of these chemokines. Lymphotactin 
is also expressed in activated CD8+ T cells and shows chemotactic activity for 
lymphocytes but in contrast to the other chemokines not for monocytes or neutrophils 
18, 24. 
Chemokines induce cell migration and activation by specifically binding to G protein-
coupled receptors which are expressed on subgroups of leukocytes 25-27. Till today, 
four CXC chemokine receptors, eight CC chemokine receptors and one CX3C 
chemokine receptor have been identified In humans 25. The chemokine receptors can 
be found on the surfaces of different types of leukocytes. The expression of the 
different receptors is partly restricted to some cell types, whereas others can be 
found on a broad range of leukocytes. Moreover, some of the receptors are 
constitutively expressed on cells, while others are induced 25. In Figure 3, 
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chemokines and their receptors are listed. Additionally, the cells expressing the 
chemokine receptors are indicated. 
The association of chemokines with glycosaminoglycans (GAGs) is of crucial 
importance in the process of leukocyte recruitment. The establishment of 2-
dimensional chemokine gradients over endothelial cells, further inducing leukocyte 
recruitment and migration through tissue, is thought to be initiated by the interaction 
between chemokines and GAGs 28. In addition, chemokine receptors can form 
heteromeric oligomers with other receptors, and crosstalk interactions can affect 
ligand-induced signaling through heterologous desensitization 9, 29-31. Chemokines 
activate seven-transmembrane G protein-coupled receptors, making them very 
attractive therapeutic targets for the pharmaceutical industry 9. 
In addition to the pivotal role of chemokines in basal and inflammatory leukocyte 
locomotion and trafficking 32, 33, certain chemokines are able to elicit a variety of other 
responses affecting leukocyte adhesion, activation and degranulation, mitogenesis 
and apoptosis 15. In addition to these properties, chemokines also exert crucial 
actions on other, non-immune cell types as endothelial cells, smooth muscle cells 
and epithelial cells. The effects of chemokines on endothelial cells result in 
stimulating (angiogenic) or inhibiting (angiostatic) effects 34, 35. Due to all these 
aspects, various interventions addressing the diversity of chemokine functions 
demonstrate the importance for the development of new therapeutic approaches. 
These include prevention of the receptor–ligand interaction, prevention of the 
chemokine–glycosaminoglycan interaction, prevention of heteromerization, interfering 
with the signalling pathways that are induced upon receptor activation and 
modification of receptor trafficking pathways 9, 12. 
Introduction 
 8
 
Figure 3 Summary of chemokines and their receptors and expressing cell types. Chemokines are subdivided 
into four families on the base of the relative position of the cystein residues in the protein (left). Chemokine 
receptors are GPCR expressed on subgroups of leukocytes (right) 
25
 
 
 
Introduction 
 9
I.3.2. Selectins and Integrins 
Selectins are a family of adhesion molecules which mediate the initial capture of 
leukocytes from the bloodstream to the blood vessels, before they firmly adhere and 
migrate at sites of tissue injury and inflammation 36. The family of selectins comprises 
of three different cell-surface molecules: L-selectin, E-selectin and P-selectin. L-
selectin is only expressed on hematopoietic cells at specific stages of their 
differentiation, including the majority of circulating neutrophils, monocytes, 
eosinophils, T cells and B cells. The expression of L-selectin is forfeit from the cell 
surface right after their activation. Due to the broad range of L-selectin expression it 
plays a pivotal role in leukocyte lineages trafficking 37, 38. On the contrary, E-selectin 
is only expressed on endothelial cells after they haven been activated by cytokines or 
bacterial endotoxins 39, 40. The third cell-surface molecule, P-selectin is permanently 
found in storage granules in endothelial cells. After activating endothelial cells by 
inflammatory mediators, P-selectin is transported to the cell surface 41, 42. Crucial 
properties of all the selectins are that they promote leukocyte attachment and rolling 
under shear stress and furthermore force leucocytes to enter into tissues 38, 43, 44. 
Rolling is required for ultimately firm adhesion to blood vessel under flow conditions. 
However, unless integrins are involved no firm adhesion and transmigration of the 
cells into the tissue will take place. Integrins are a family of adhesion molecules with 
heterodimeric membrane proteins that consist of an α and a β subunit. These 
subunits are aligned via noncovalent bonds and as a complex they are transported to 
the cell surface 38, 45. When neutrophils adhere to the luminal endothelial surface, 
their shape changes and adopts bipolar characteristics of motile cells 46, 47. The 
adhesion is followed by transendothelial migration and guides the neutrophils to 
infiltrate the inflamed tissue 38. 
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Figure 4 shows how chemokines are secreted at sites of inflammation by resident 
tissue cells, leukocytes, and cytokine-activated endothelial cells and generate a 
chemokine concentration gradient surrounding the spot of inflammation and on the 
surface of the overlying endothelium. Leukocytes rolling on the endothelium in a 
selectin-mediated process are brought into contact with chemokines. Chemokine 
signalling activates leukocyte integrins, leading to firm adherence and extravasation. 
The recruited leukocytes are activated by local proinflammatory cytokines 25. 
 
Figure 4 Scheme on chemokine regulated leukocyte movement and the role of selectins and integrins. 
Chemokines are secreted at sites of inflammation by e.g. recruited leukocytes and activated endothelial cells, and 
establish a chemokine concentration gradient surrounding the spot of inflammation. Leukocytes are brought in 
contact with chemokines through rolling on the endothelium in a selectin mediated process. Furthermore, 
chemokine signalling activates leukocyte integrins, leading to firm adherence and extravasation. 
25
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I.4. Therapies after Myocardial Infarction 
The main goals of myocardial infarction therapies are an adequate restoration of 
normal coronary blood flow and a maximal rescue of functional myocardium 4. These 
objectives can be achieved by a variety of interventions and coherent therapies. 
I.4.1. Classical Therapies and Medications 
When myocardial infarction is diagnosed a variety of medications exist to reduce pain 
and to prevent a secondary cardiovascular event. 
Anti-platelet therapies such as aspirin and/or clopidrogel have shown to reduce 
mortality from myocardial infarction 48. Due to the adhesion of a small collection of 
activated platelets at the spot of an intimal disruption in an unstable atherosclerotic 
plaque a coronary thrombus can develop. By administering aspirin, additional platelet 
activation, adhesion and cohesion can be prevented. These mechanisms are blocked 
because aspirin inhibits the ability of the COX enzyme to synthesize the precursor of 
thromboxane production within platelets, which under common circumstances 
concatenate platelet molecules together to build up a filler over an injured blood 
vessel wall 4, 49. 
Another accepted therapeutically treatment is the administration of beta-blockers to 
reduce the morbidity and mortality in myocardial infarction. Beta-blockers decrease 
the incidence of recurrent ischemia, reinfarction and if administered early enough, to 
reduce the size of infarct myocardium. This is accomplished because of the ability to 
reduce the renin secretion from the kidney, which then lowers the oxygen demand of 
the heart by lowering the extracellular volume and increasing the capacity of the 
blood to carry oxygen. Additionally the inhibition of the postganglionic function of the 
sympathetic nervous system reduces the heart rate and thus greatens the ejection 
fraction of the heart 50, 51. 
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Angiotensin converting enzyme inhibitors or short ACE-inhibitors are an additional 
medication utilized after myocardial failure. Angiotensin II is a crucial substance in 
regulating the contracting muscles surrounding blood vessels and consequently 
leads to the narrowing of these vessels. ACE-inhibitors force the converson of 
angiotensin I into angiotensin II in the blood. ACE inhibitors are drugs which inhibit 
the activity of the enzyme ACE resulting in a decreased production of angiotensin II. 
As a consequence, blood vessels enlarge or widen and this results in a reduced 
blood pressure. This lowered blood pressure eases the heart to pump and therefore 
can recover the function of a failing heart 52. 
Further commonly used drug therapies are statins. Statins belong to cholesterol 
level-lowering drugs by inhibiting the rate-controlling enzyme HMG-CoA reductase. 
This enzyme plays a pivotal role in cholesterol production in the liver and has been 
associated with cardiovascular diseases 53. Regularly, mammalian cells suppress 
HMG-CoA reductase by cholesterol derived from the internalization and degradation 
of low density lipoprotein (LDL) via LDL receptor and oxidized species of cholesterol. 
The inhibition of the reductase leads to LDL receptor expression in the liver which is 
followed by an elevated catabolism of plasma LDL and subsequently reduces the 
plasma concentration of cholesterol, an important determinant of athersoclerosis 54, 
55. Hence, it is widely accepted that statins promote plaque stabilization which 
possibly will avoid myocardial infarction 56. 
Besides medical interventions, surgical treatments are regularly used to treat or 
prevent myocardial infarction. One way is the mechanical widening of narrowed or 
closed blood vessels due to atherosclerosis, called angioplasty. For this purpose, an 
unfilled and collapsed balloon attached to a guide wire is passed into the narrowed 
spot in the artery and is then blown up to a fixed size. Because of this inflation the 
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balloon crushes the fatty deposits, therefore opens the blood vessel and allows again 
the blood to flow. Finally, the balloon is drained and removed from the artery 57, 58. 
To avoid myocardial infarction, stents can be implanted into coronary arteries. 
Treating a closed coronary artery with a stent almost follows the same principal as 
angioplasty. The stent, in its collapsed form, is attached to the outside of a balloon 
catheter and is directed to the place of interest. There, the balloon catheter is 
expanded until the vessels original diameter is reached and the stent is extended to 
its appropriate size 58. 
Although angioblasty and stent transplantation are widespread methods used, some 
side effects still remain. Restenosis, the renarrowing of a blood vessel after surgical 
intervention, remains a major limitation especially in case of bolloon angioplasty. This 
pathology is caused by neointimal formation and constrictive remodelling. Neointimal 
formation is initiated by arterial injury associated with a loss of contractile phenotype 
in tunica media. This further leads to vascular smooth muscle cell migration from the 
tunica media into the intima. Migrated vascular smooth muscle cells play a major part 
in the intimal thickening by the excessive synthesis of extracellular matrix and 
proliferation 6, 59, 60. Inward constrictive remodelling, the increase in contractile forces 
leading to lumen narrowing, is also considered as a major cause of delayed failure of 
angioplasty60. 
For stent implantation it is crucial that the stent is in direct contact with the vessel wall 
to diminish the risk of complications such as thrombus formation. A critical event after 
stent implantation is the so called in-stent restenosis. In this pathological event, the 
artery recognises the stent as a foreign body and respons by raising an immune 
response. This causes a overgrowth of the tissue into the stent and leads to a further 
increase of stent and artery narrowing (Figure 5) 61. 
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Figure 5 Scheme of the pathology of in- stent restenosis, showing the overgrowth of tissue within a stent 
62
 
 
Although these surgical interventions are successful in preventing myocardial 
infarction, the benefit is achieved at the cost of a high risk in vascular complications 
and long hospital stay 63, 64. 
I.4.2. New Therapeutical Strategies 
Chemokine Antagonists 
Various interventions addressing the diversity of chemokine functions demonstrate 
their importance for developing new therapeutic approaches. Prevention of receptor–
ligand interactions, prevention of the chemokine–glycosaminoglycan interaction, 
prevention of heteromerization, interfering with the signaling pathways could provide 
highly efficacious therapeutic strategies for the treatment of cardiovascular diseases 
9. 
For example, targeting ELR+ CXC chemokines and their receptors seems to have a 
therapeutic potential 14. The family of CXC chemokines can be subdivided on the 
basis of the presence or absence of three amino acids right next to the CXC 
sequence, namely the Glu-Leu-Arg (ELR) motif. The CXC chemokines containing this 
motif have originally been described to be potent neutrophil chemoattractants as well 
as to promote angiogenesis. On the other hand, CXC chemokines lacking the ELR-
motif are known to be angiostatic 65, 66, with one remarkable exception, CXCL12 9, 67.  
Introduction 
 15
Higher serum levels of ELR+ CXC chemokines seem to correlate with a risk profile 
for cardiovascular diseases 68, 69. But neutralizing KC (CXCL1), the mouse GRO-α 
ortholog, leads to impaired reendotheliazation and increased neointima formation 70. 
There are also multiple reports stating that ELR+ CXC chemokines can affect 
neutrophil recruitment to sites of injuries 71-73 and that neutralizing them can 
ameliorate ischemia/reperfusion-induced organ damage 71-75. These aspects should 
be considered and carefully scrutinized, when devising therapeutic strategies 
involving the ELR+ CXC chemokines 9. 
CXCL12/SDF-1 (stromal-cell derived factor-1) is an influential chemoattractant for T 
cells and monocytes, whereas it furthermore regulates the recruitment of 
lymphocytes from the blood flow to the endothelium 76 and controls mobilization of 
neutrophils and hematopoietic stem cells from and to the bone marrow 77, 78.  
Some studies found that serum levels of CXCL12 positively correlate with the number 
and functional activity of endothelial progenitor cells and therefore may play important 
roles in the pathology and healing of heart disease 79-81. On the other hand, 
interesting work by Damas and colleagues described that CXCL12 levels 
incrementally decreased among healthy individuals and patients with stable and 
unstable angina, respectively 82. 
In human atherosclerotic plaques, but not in healthy vessels, CXCL12 is strongly 
expressed in smooth muscle cells, endothelial cells and macrophages. New evidence 
came up that CXCL12 not only influences the activation and migration of leukocytes, 
but also induces platelet aggregation accompanied by an increase in intracellular 
calcium. In line, platelets express CXCR4, the corresponding CXCL12 receptor 9, 83, 
84. 
The potential of small molecule CXCR4 antagonists as therapeutic entity in 
atherosclerotic complication has been evaluated by Karshovska et al. 85. The 
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treatment of ApoE-deficient mice with the CXCR4 antagonist AMD3465 after arterial 
injury, led to a 59% reduction of neointimal area compared to the PBS-treated control 
group 85. Small molecular antagonists targeting other chemokine receptors relevant 
in the pathology of atherosclerosis, like CXCR2 and CXCR3, have further shown that 
atherosclerosis can be prevented by reduced angiotensin 2-induced leukocyte 
recruitment and lowered atherosclerotic lesion formation via a reduction of T helper 
type 1 cells in hyperlipidemic mice, respectively 86, 87. In principle, these results 
indicate that small molecule antagonists of chemokine receptors are promising for the 
treatment of atherosclerosis. A chronic treatment with AMD3465 on the other hand, 
exacerbated diet-induced atherosclerosis due to the mobilization of neutrophils and 
their elevated recruitment to atherosclerotic plaques 88.  
Recently, CXCL12 has also been identified as a potent tissue-protective and 
regenerative factor in a mouse model of ischemia and reperfusion. In this model, 
administration of another CXCR4 antagonist AMD3100 reduced scar formation and 
improved cardiac contractility 89. Additionally, a prolonged survival of hypoxic 
myocardium and favourable angiogenesis has been observed after intracardiac 
administration of CXCL12 90. Further beneficial effects of CXCL12 may be due to 
enhanced recruitment of blood-derived progenitor cells expressing CXCR4 into the 
injured myocardium via activated chemokine-mediated pathways, finally resulting in 
neovascularization and enhanced preservation of cardiomyocytes 91. Although an 
undisputed therapeutic potential of CXCL12 has been shown, it has to be kept in 
mind that CXCL12 in humans can be cleaved by matrix metalloprotease-2 generating 
a neurotoxic remnant polypeptide 92. Consequently, to evolve an effective therapy to 
treat myocardial infarction by using CXCL12, a chemokine molecule resistant for this 
protease might be required 9, 93. In summary, the administration of CXCL12 as well as 
the administration of a CXCR4 antagonist is beneficial for myocardial recovery after 
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infarction. Nevertheless, it has to be kept in mind that the detailed underlying 
mechanisms are not completely understood. Consequently, the classification of 
CXCL12 as a ‘good’ or ‘bad’ player regarding the treatment of myocardial infarction is 
not feasible now. 
Cell therapy 
Besides the current therapeutic strategies to prevent the progression of cardiac 
failure, new stem- and progenitor-cell therapies came up to functionally regenerate 
the injured myocardium. In animal models, it already has been shown that 
transplanting adult stem cells into the myocardium leads to enhanced left ventricular 
function after acute myocardial infarction due to improved neovascularization and 
diminished fibrosis 94, 95. Clinical trials have confirmed that autologous progenitor 
cells distinctively improve left ventricular function and vascularization in patients 
suffering from acute myocardial infarction. Besides the pathological benefit of the cell 
therapy, safety and feasibility has been confirmed 96-98. 
Endothelial progenitor cells (EPC) are present in the peripheral blood in adults. They 
have the potential to differentiate into mature endothelial cells in vitro. When these 
differentiated endothelial cells are used for transplantation in animal ischemic tissue 
models, they positively support vasculogenesis 99. Moreover, after inducing 
myocardial infarction in rats, intravenously applied EPCs migrate into the ischemic 
infarcted zone and augment hemodynamic functions 95. The number of EPCs in each 
human is limited and therefore their therapeutically application is restricted. However, 
human EPCs can be expanded to a clinically relevant number of cells by using cell 
culture methods. When these in vitro expanded EPCs are transplanted 
intramyocardially after ischemic/reperfusion of rats’ hearts, the cells start proliferating, 
building up vascular structures and therefore advance left ventricular function 100. In 
addition, clinical studies have proven that the intracoronary administration of EPCs 
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leads to an up-regulated ejection fraction after an acute myocardial infarction 101. 
Although EPCs have lead to graet achievements in cell therapy, there is still an 
ongoing discussion about EPCs and their definite characterisation. Recently, it was 
reported that two different types of EPCs have comparable angiogenic capabilities, 
the so called early EPCs and late EPCs 102. Early EPCs are similar to the progenitor 
cells first reported as EPCs 103, which have been used in most of the angiogenesis 
trials previously mentioned. Lately, these cells have been reffered to as monocyte-
derived circulating angiogenic cells 104, 105 or as early EPCs 106. Early EPCs positive 
for CD14, produce spindle-shaped cells but do not give rise to endothelial outgrowth. 
Whereas early EPCs negative for CD14 give rise to endothelial outgrowth 106, 107. 
Late EPCs are similar to the circulating bone marrow-derived endothelial cells 106, 108 
or outgrowth endothelial cells 109 which are characterized by late outgrowth and 
cobblestone appearance 107. 
With myocardial infarction, a massive number of cardiomyocytes die and loose their 
function which results in gained wall stress of the remaining myocardium. This 
exposure triggers a sequence of cellular and physiological processes causing an 
incremental expansion of the preliminary infarct size and distention of the left 
ventricular lumen and is further associated with the substitution of cardiomyocytes 
with fibrous tissue in the ventricular wall 110, 111. The regression and functional 
regeneration of a developed myocardial necrosis is severely restricted due to the low 
mitogenic potential of cardiomyocytes 112. The generation of a surrogate tissue for the 
injured myocardium is a big challenge as it needs to develop a capillary network to 
assure the great oxygen supply. Additionally, to guarantee a contracting heart 
muscle, the cells need to be located in the correct alignment to receive coordinated 
electrical signals 113. Promising approaches in regenerating wounded myocardium 
were achieved by cardiac progenitor cells (CPC). Although, studies have shown that 
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isolated CPCs from rat and human hearts can give rise to cardiomyocytes, induce 
large scale regeneration of myocardial infarcts and the formation of new myocardium 
and vessels, this field of research is one of the most controversial 113, 114. 
I.5. Angiogenesis 
Angiogenesis is the growth of new blood vessels out of pre-existing capillaries. This 
process takes place throughout life in health as well as in disease, starting in utero 
and continuing on through old age. Capillaries formed by the process of 
angiogenesis are needed in all tissues of the body for exchanging nutrients and 
metabolites. Oxygen is one of the most important factors in regulating metabolic 
activity and therefore in altering angiogenesis and hence in the formation of new 
capillaries. As this mechanism has been recognized to be crucial in tissue survival, 
angiogenesis became of great interest as therapeutic target in ischemic heart 
disease, peripheral artery disease and wound healing 115. 
There are two types of angiogenesis known: sprouting angiogenesis and intus-
susceptive angiogenesis. Sprouting angiogenesis is better understood having been 
discovered approximately 200 years ago and having been in the focus of 
researchers. Sprouting angiogenesis is divided in several steps starting with 
enzymatic degradation of capillary basement membrane, followed by endothelial cell 
(EC) proliferation, directed migration of ECs, tube formation by endothelial cells, 
vessel fusion, vessel pruning, and finally pericyte stabilization. The development of 
new blood vessels is initiated in inadequately perfused tissue when oxygen-sensing 
mechanisms recognise a stage of hypoxia which makes the formation of new blood 
vessels to ensure the metabolic requirements of parenchymal cells necessary. Many 
different parenchymal cell types like myocytes or hepatocytes, react to hypoxic 
environments by secreting proangiogenic growth factors, cytokines and/or 
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chemokines. The secretion of these different factors finally initiates the process of 
angiogenesis in a connected but currently only partially understood manner 115, 116. 
The most prominent angiogenic factors are the members of the vascular endothelial 
growth factor (VEGF) family. As they are the most potent modulators in vascular 
biology, their role in vasculogenesis 117, vascular maintenance in embryogenesis 118 
and adults 119 and especially in angiogenesis is of exceptional importance. First, 
VEGF-A, the master regulator of angiogenesis 120 and vascular permeability 121 was 
discovered, followed by four other members of the human VEGF family: VEGF-B 122, 
VEGF-C 123, VEGF-D 124 and placental growth factor (P1GF) 125. VEGFs bind and 
activate their receptors (VEGF-R), which belong to the family of the tyrosine kinase – 
signalling receptors 126, VEGF-A, herein further referred to as VEGF, thereby 
promotes endothelial cell proliferation, survival and migration 127. Due to these 
exceptional effects on blood vessel formation, VEGF became a major research target 
with respect to therapeutic vascular growth in myocardial infarction. However, clinical 
trials have provided dissent data on the clinical efficacy and usefullness of VEGF in 
regard to positively influencing angiogenesis 128, 129. 
I.5.1. Chemokines and Cytokines and their Receptors in 
Angiogenesis 
Critical players in angiogenesis are the chemokines of the CXC family. Due to their 
unique features, the basis of their structure and receptor binding, their individual 
ligands show either angiogenic or angiostatic biological activity in angiogenesis 
regulation 130. The reason that CXC chemokines are either pro-angiogenic or 
angiostatic is the presence or lack, respectively, of three amino acid sequences. This 
sequence, glutamic acid-leucine-argenine, the so called ‘ELR’ motif is directly 
adjacent to the CXC structure 66. 
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In humans, two receptors are known to promote the signals of ELR+ CXC 
chemokines. These are CXCR1 and CXCR2. As only in the last five years data came 
up identifying a functional murine homologue for the human CXCR1 131, 132, called the 
mCXCR1-like, CXCR2 is considered the most prominent pro-angiogenic chemokine 
receptor, mediating all murine ELR+ CXC chemokine signals. Convincing data were 
published showing that the angiogenic features of the ELR+ CXC chemokines are 
only mediated via CXCR2 in human as well as in mice. As indicated in Figure 3, only 
IL-8 (CXCL8) and GCP-2 (CXCL6) specifically bind to CXCR1, but angiogenesis in 
humans is mediated by all ELR+ CXC chemokines 65. Another point strengthening 
the pivotal role of CXCR2 in angiogenesis is the fact that both CXCR1 and CXCR2 
are present on mRNA level of unstimulated endothelial cells 133 but only the 
expression of CXCR2 is needed for endothelial cell chemotaxis 65, 134. These data 
were supported by the finding that the human endothelial cell response to CXCL8 
can be blocked by neutralizing CXCR2 or inhibiting its intracellular signalling pathway 
135. Additionally, in vivo studies show the importance of CXCR2 in mediating ELR+ 
CXC chemokine-induced angiogenesis. CXCR2 immunoneutralization in rats 136 as 
well as CXCR2 deficiency in mice 137 have shown inhibited vascularization and 
impaired angiogenesis, respectively. 
The CXCL12-CXCR4 ligand-receptor axis has been primarily associated with cancer 
cell migration inducing metastasis 17, but other data are also implicating the CXCL12-
CXCR4 axis in angiogenesis 81, 138-140. It has been shown that CXCL12 promotes 
tissue regeneration by mediating progenitor cell recruitment into ischemic areas 141, 
whereas CXCR4 signalling can positively stimulate proliferation and cell survival, and 
by this, angiogenesis 142, 143. In case of vascular damage, CXCL12 expression is 
upregulated because of apoptosis and cell stress, starvation, hypoxia and is 
recruiting smooth muscle progenitor cells via CXCR4 to the site of injury 144, 145. As 
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ischemia is the trigger for angiogenesis, the effect of CXCL12 on regenerating 
myocardial infarction via angiogenesis has been in the focus of several researchers. 
Exogenous CXCL12 applied to the myocardium or overexpressed in transplanted 
cardiomyocytes 91, 146, is able to induce therapeutic angiogenesis and progenitor cell 
homing, increases capillary density and finally improves cardiac function after 
myocardial infarction 93, 147. The communication between CXCL12 and CXCR4 
seems to be an elemental target in improving neo-myoangiogenesis and left 
ventricular remodelling 148 and implicitly improving stem cells therapy after myocardial 
infarction 91, 148. These findings indicate the significance of CXCL12 and CXCR4 in 
the process of angiogenesis in the ischemic myocardium. Nevertheless, the intrinsic 
role of endogenous CXCL12-CXCR4 in myocardial infarction is far from being 
conclusively understood. 
The CXC chemokine keratinocyte-derived chemokine (KC) contains the ELR motif, 
giving evidence for being a potent angiogenic factor 65. KC represents the ligands for 
CXCR2 in mice and via binding to CXCR2 it promotes tumor growth 149. Besides the 
role of KC in tumor growth, there is evidence from rodent models that KC is also 
involved in endothelial recovery after arterial injury 70. Liehn et al. have confirmed the 
significant role of KC and its receptor CXCR2 in endothelial recovery. First it was 
shown that endothelial cell-derived and exogenous KC promoted endothelial wound 
repair after arterial injury. Secondly, KC triggered endothelial cell chemotaxis in 
migration assays and thirdly it was possible to inhibit the effects of KC by blocking 
CXCR2 using a mAb 70. These data illustrate that blocking KC can directly impair 
endothelial migration and therefore angiogenesis via CXCR2. 
While most of the literature in consideration of chemokines in regulating angiogenesis 
was focused on the CXC chemokine family, the members of the CC chemokines 
were mostly neglected in this process. But the CC chemokines, CCL11, CCL16 and 
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CCL21 are also implicated in angiogenesis 150-152. However, the most intensly studied 
CC chemokine is CCL2 (MCP-1). Endothelial cells express the CCL2 surface 
receptor CCR2 153. Via this receptor, CCL2 can promote chemotactic cell attraction 
and tube formation in vitro 36, 154. Besides these in vitro data, the role of CCL2 in vivo 
has been confirmed by models of inflammatory angiogenesis 155. This experimental 
mouse model demonstrated that CCL2 can generate neovscularization within the 
sponge compartment and that inflammatory cells influx into this sponge can be 
modulated by exogeneous administration of this CC chemokine. 
I.6. Macrophage Migration Inhibitory Factor 
Almost 50 years ago, macrophage migration inhibitory factor was one of the first 
cytokines identified 156. Until 1989 and 1993, when human MIF and murine MIF were 
cloned for the first time 157, 158, the biological activities of MIF were vague. Since then, 
MIF has been in focus of intense investigation. 
At first, it was shown that MIF controls T-cell activation and allocates an unknown but 
pivotal role of MIF in antigen specific immune response 159. Hence, it was thought 
that T-cells were the most important cellular source of supply of MIF in the immune 
system 156. However, in addition to T-cells, MIF is generated by other cell types of the 
immune system such as the monocyte/macrophage lineage 160, neutrophils 161, 
endothelial cells 162 and eosinophils 163. MIF is constitutively produced and stored in 
intracellular pools by these cells and consequently does not require de novo protein 
synthesis prior to its secretion 164, 165. The molecular mechanisms leading to its 
release from the pools can be caused by a variety of stimuli. MIF is rapidly released 
by cells of the anterior pituitary gland after exposure to the endotoxin 
lipopolysaccharide (LPS) found at the outer membrane of gram-negative bacteria 158. 
MIF is also released by cells of whole blood which are stimulated with heat-killed 
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Streptococcus pneumoniae, followed by a MIF-specific antibody reduces cytokine 
production, which leads to an increases survival in a mouse model of S. pneumonia 
induced pneumonia (Calandra et al., unpublished observations) 164. Also 
glucocorticoids have been reported to stimulate the release of MIF from T cells 166. 
Recently it was found that also hypoxia can induce endothelial secretion of MIF 167. 
Additionally to the immune system, MIF is broadly distributed in a number of tissues, 
like the heart, liver, lung, pancreas, kidney, brain or bones 164. There are two 
specifics about MIF tissue distribution. First, cells and tissues in direct contact with 
the humans’ natural environment express MIF, like the lung 159, the skin 168 and the 
gastrointestinal 169 tract. Secondly, a number of organs of the endocrine system, 
mainly involved in stress responses, secrete an elevated level of MIF 170. 
I.6.1. MIF receptors 
It is generally accepted that cytokines act via binding to cognate receptors present on 
target cells and thereby activating signaltransduction pathways, gene transcription 
and expression of downstream effector molecules. First studies about MIF triggered 
signalling have shown that MIF induces phosphorylation and activation of the ERK1-
MAPK pathway and cell proliferation 158. This pathway activation is protein kinase A-
dependent and is additionally associated with an increased cytoplasmic 
phospholipase A2 (PLA2) enzyme activity. As PLA2 is a pivotal activator of the pro-
inflammatory cascade, the ERK1-MAPK mediated induction of PLA2 seems to be a 
mechanism due to which MIF possibly disables the immunosuppressive of steroids 
158. CD74, the cell surface form of the major histocompatibility complex (MHC) class 
II-associated invariant chain, was identified to be a cell surface receptor for MIF 171. 
Furthermore, Leng et al. showed that MIF binds to CD74 by a high affinity interaction 
and that this surface protein is essentially required for MIF-mediated ERK1 
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phosphorylation and cell proliferation 171. But as not all cells targeted by MIF express 
CD74 on their surface, like as neutrophils 161,164, the molecular mode of action and 
functional receptors of MIF in inflammatory diseases remained unclear. 
Recently two additional MIF receptors were identified. It was demonstrated that MIF 
is a noncognate CXCR ligand which extends the range of possible binding partners 
of MIF in the chemokine receptor family 170. For CXCR2 activation by its cognate 
ligands an ELR-motif is required 170. MIF is able to improve its chemoattractant 
activity to monocytes and neutrophils through CXCR2, both crucial mechanisms in 
inflammatory pathologies like atherosclerosis 170. Hence, it was shown that the 
chemoattraction of MIF to monocytes was not only based on CXCR2 binding but also 
on the basis of CD74 participation, which is colocalized with CXCR2. These data 
suggest that MIF is signalling via a CXCR2/CD74 complex. Nevertheless, MIF is able 
to bind to CXCR2 alone but it seems that binding to this receptor complex further 
enhances G-protein coupled receptor (GPCR) activation. Besides CXCR2, MIF also 
is a functional ligand for CXCR4. By interacting with this receptor, it can promote T-
cell recruitment 170. The finding that blocking MIF impaired CXCR4-supported T-cell 
recruitment 170 is of high importance as this mechanism is crucial in driving 
atherosclerotic lesion development. Based on these findings MIF is a functional 
ligand for CXCR2 and CXCR4 and thus can regulate the recruitment of monocytes 
and T-cell, respectively, into inflammatory regions of atherogenic vessel walls 170. 
I.6.2. Function of MIF 
MIF in Myocardial Infarction 
The definite role of MIF in cardiovascular diseases, especially in myocardial infarction 
is not clarified yet. In previous studies it has been shown that MIF is upregulated in 
vascular endothelial cells and smooth muscle cells in atherosclerotic plaques, 
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associated with macrophage accumulation and plaque formation and progression 172, 
173. In the context of myocardial infarction it was demonstrated that, in patients with 
acute myocardial infarction, the level of MIF was significantly elevated and was 
higher than in patients with reversible myocardial ischemia 174. Additionally, a model 
of acute myocardial infarction in rats has shown that in both normal and sham-
operated rats, MIF mRNA and protein expression on myocytes was constitutively at 
low levels. On the contrary, MIF mRNA was rapidly upregulated by surviving 
myocytes in the infarcted region compared to noninfarcted regions. This was 
accompanied by an increase in MIF protein expression after one day after acute 
myocardial infarction and macrophage infiltration in this tissue 175. 
A previous study has shown that AMP-activated protein kinase (AMPK) orchestrates 
the regulation of energy-generating and -consuming pathways, and protects the heart 
against ischaemic injury and apoptosis 176. In connection with this finding, the 
possible role of MIF in AMPK activation was investigated 177. It was proven that MIF 
is released in the ischaemic heart, where it stimulates AMPK activation through 
CD74, promotes glucose uptake and protects the heart during ischaemia-reperfusion 
injury 177. The modulation of the activation of the cardioprotective AMPK pathway by 
MIF during ischaemia, functionally linking inflammation and metabolism in the heart 
was shown. Additonally, it was anticipated that genetic variation in MIF expression 
may impact on the response of the human heart to ischaemia by the AMPK pathway, 
and that diagnostic MIF genotyping might predict risk in patients with coronary artery 
disease 177. Reactive oxygen species also play a pivotal role in the pathology of 
ischemia/reperfusion, can be generated by cardiomyocytes 178. Reactive oxidative 
stresses as well as hypoxia stimulate cardiomyocytes to secrete MIF through a 
protein kinase C-dependent pathway in the myocardium 179, 180. 
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Thus, MIF may play a crucial role in the pathology of myocardial infarction and 
influence macrophage infiltration into the infarcted tissue and their proinflammatory 
role in myocyte injury after infarction. 
MIF in Atherosclerosis 
MIF has been found to be a key element in vascular processes giving rise to 
atherosclerosis. During the development of atherosclerotic lesions in humans, rabbit 
and mice, the expression of MIF is upregulated in endothelial cells, smooth muscle 
cells and macrophages 178. Although, in a large, prospective, population-based case-
cohort study, MIF serum levels failed to associate with the incidence of 
cardiovascular diseases 181, it has been investigated that MIF is expressed over 
different stages of human atherosclerosis 173. MIF was present at low levels in 
endothelial cells and vascular smooth muscle cells of internal mammary arteries 
(IMAs) with a normal histology and, importantly, was upregulated during the 
progression of atherosclerosis toward inflammatory stages 173. Another study has 
demonstrated the importance of MIF in the pathology of atherosclerosis 182. 
Immunoneutralization of MIF significantly reduced neointimal macrophage infiltration 
and macrophage derived foam cell formation in a hypercholesterolemic model of 
vascular injury 182. Moreover, an involvement of endothelial MIF in monocyte arrest in 
shear flow was shown. The inhibition of MIF-dependent monocyte recruitment may 
thus be an important mechanism for plaque stabilization 182. 
MIF, as a monomer, has very close structural similarities to CXCL8 dimers 183. 
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Figure 6 Crystal structure of MIF and its structural affiliated CXCL8 
170, 183
 
 
Accordingly, it has been shown that, besides CXCL8, MIF can induce monocyte 
arrest on endothelial layers through activation of CXCR2 and that this activity was 
associated with an immobilization of MIF on aortic endothelial cells. These findings 
suggest that MIF is a noncognate CXCR2 ligand that binds to CXCR2 and exercizes 
a chemokine-like arrest function when present on the surface of endothelial cells 170, 
184. Further indications for the relevance of MIF in progression of atherosclerosis in 
vivo have been gained by a study from Burger-Kentischer et al. 184. The treatment of 
ApoE-/- mice with a neutralizing anti-MIF antibody led to a reduction of inflammatory 
mediators typically associated with atherosclerosis and was also accompanied with a 
small yet significant reduction of aortic plaque area.  
All these results are leading to the conclusion that MIF is produced locally in key cells 
in all stages of lesion evolution and thus, plays an important role during the 
progression of human atherosclerosis. 
MIF in Angiogenesis 
Recent in vitro and in vivo studies suggest an important relationship between MIF 
expression, tumor angiogenesis and tumor progression 185. 
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In regard to increased cell proliferation in vitro because of MIF, it was shown that MIF 
in human primary and metastatic colon cancer tissue is higher expressed than in 
normal colonic mucosal tissue 162. This, and noumerous other findings, led to the 
hypothesis that MIF is involved in tumorigenesis. These proposals were supported by 
the findings that MIF protein and its mRNA were expressed in colon 26 carcinoma 
cells. mRNA levels of MIF were able be up regulated in colon 26 cells in response to 
TGF-β, PDGF and β-FGF, factors important in tumour invasion 186, tumour size 187, 
and cancer cell proliferation 188, respectively. Moreover, the transfection of colon 26 
cells with anti-sense MIF plasmid significantly suppressed their cell proliferation. On 
the other hand, the cell growth of colon 26 cells was only minimally affected by 
exogeneous recombinant MIF, leading to the speculation that an elevated 
intracellular MIF level is critical for cell growth rather than extracellular MIF 162. 
The first links between MIF and cancer in vivo were provided by experimental studies 
in mice. It was first reported by Chesney et al. that MIF plays a pivotal role in new 
blood vessel formation 189. Neutralizing anti-MIF antibody administration to mice 
significantly obstructed the growth of B-cell lymphoma and consequently reduced 
tumour growth. This effect was accompanied with a remarkable reduction in tumor 
angiogenesis 189. The same study provided evidence that in vivo, MIF is 
predominately expressed by tumor endothelium and in vitro, microvascular 
endothelial cells secrete MIF protein and also need MIF for proliferation. Additionally, 
MIF turned out to be essential for the outgrowth of new vessels in vivo. This was 
detected by an in vivo model of angiogenesis using matrigel plug implantation into 
BALB/c mice. The treatment with anti-MIF antibody was associated with a striking 
reduction of the number as well as the diameter of new blood vessels formed 
compared to the control IgG-treated group 189. These data provided evidence of MIF 
being a crucial player in angiogenesis but this needs to be further investigated. 
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I.7. Endothelial Progenitor Cells 
Using stem and/or progenitor cells in cardiovascular cell therapy is an auspicious tool 
for repairing and regenerating cardiovascular cells in diseased patients. Pathbreaking 
preclinical studies provided evidence that the blood of human adults contains 
endothelial progenitor cells, with the attribute to enhance neovascularization in 
immune-deficient mice suffering from hindlimb ischemia 103, 190. Impaired endothelial 
function is known to be a marker for cardiovascular diseases 191 but in addition 
several studies have shown that also a reduced number in native circulating EPCs 
correlates with diminished endothelial function 17 and cardiovascular diseases in 
patients 192, 193. These findings suggested that native EPCs could potentially promote 
endothelial function and cardiovascular outcomes. Nevertheless, recent controlled 
clinical studies transplanting EPCs 96 or other bone marrow mononuclear cells 194 in 
patients with myocardial infarction failed to improve cardiac function compared to 
control patients 195. The reason for this failure seems to be the enormous variety in 
methods and cells used in studying the effect of EPCs on cardiovascular diseases 
rather than the nature of the EPCs used 96, 106, 190, 196. Therefore an appropriate 
definition of EPCs and a better mechanistic understanding is necessary. 
Asahara et al published the first detailed description of isolation of putative progenitor 
endothelial cells for angiogenesis in 1997 103. These cells were isolated from human 
peripheral blood using magnetic microbeads, selecting only the CD34-positive cells 
103. After plating on fibronectin-coated surface, the cells grew into cells with 
endothelial characteristics. Later it was further discovered that functional early EPCs 
additionally express CD133, CD34 and VEGFR-2 but not vascular endothelial (VE) 
cadherin and von Willebrand factor (vWF) 197, 198. But there were reports suggesting 
the existence of another type of EPC that originated from bone marrow, circulated in 
peripheral blood, and showed different morphology and proliferation pattern from 
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EPC that Asahara reported 103, 108, 109. Hur et al. were the first who cultured two 
different types of EPC from adult peripheral blood and called them early EPC and 
late EPC according to their time-dependent appearance 102. The cells shared some 
endothelial phenotypes; however, they showed different morphology, proliferation 
rate, and survival features 102. This study has shown that early EPC are similar to the 
progenitor cells first reported as EPCs 103, which have been used in most of the 
angiogenesis trials. Lately, these cells also have been reffered to as monocyte-
derived circulating angiogenic cells 104, 105. Early EPCs gradually lose CD45 and 
CD31 expression and gain low-level expression of KDR and VE-cadherin 102. These 
early EPCs can either be positive for CD14 and produce spindle-shaped cells but do 
not give rise to endothelial outgrowth, or negative for CD14 and give rise to 
endothelial outgrowth 106, 107. Late EPC were characterized by an upregulation of 
KDR expression and a higher and longer sustained expression level of VE-cadherin 
and vWF but also by the gradually decrease of CD45 102. Late EPCs are similar to 
the circulating bone marrow-derived endothelial cells 106, 108 or outgrowth endothelial 
cells 109, which are characterized by late outgrowth and cobblestone appearance 107. 
Furthermore it can be distinguished between previous mentioned early and late 
EPCs and peripheral circulating EPCs, which are more mature and have lost CD133 
but still express CD34 and VEGFR-2 199. Thus, the loss of CD133 seems to be a sign 
of transforming circulating EPCs into a more mature endothelial cell population 199, 
200. Circulating EPCs furthermore are positive, in different intensities, for endothelial 
markers such as CD31, VE-cadherin, vWF, and, due to stimulation, E-selectin 103, 201, 
202. In summary, circulating EPCs are positive for CD34/VEGFR-2/CD31/VE-cadherin 
and begin tho express vWF 199. 
Consequently, up to now there are distinct types of EPCs known to be present in 
human peripheral blood at once. Although it seems that EPCs are fully characterized, 
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there is still an ongoing discussion about EPCs and there definit depiction, there is no 
doubt about their capacity to enhance angiogenesis and vascular repair in 
experimental models 95, 104, 203, 204. The understanding of the cellular and molecular 
basis for the formation, remodeling, repair and regeneration of blood vessels by 
EPCs is still under intense investigation. Tabel 1 gives an overview on the variety of 
characteristics of early EPC and late EPCs (OECs). 
Tabel 1 List of characteristics of early EPCs and late EPCs (OECs). This table gives a short overview on the 
different charactersitics of early EPCs and late EPCs accorting to their morphology, growth pattern in vitro, 
surface antigen expression and angiogenic potential (adapted from Yoon et al.) 
107
 
 
I.7.1. Embryonic Endothelial Progenitor Cells 
In 1998, Hatzopoulus et al. established a potentially additional approach to analyze 
the molecular basis of vascular development that involves EPCs 205. Therefore, his 
group isolated and cultured early mesodermal embryonic cells, having endothelial 
progenitor cell properties with unlimited, stem cell-like growth and a stable phenotype 
in culture. RNA and protein analysis demonstrated that these so called embryonic 
EPCs (eEPCs) express a subset of mesodermal, Fgf-3, and early endothelial cell 
markers like Tie-2, VEGFR-2, vWF and thrombomodulin (TM) 205. In vitro 
differentiation of eEPCs through retinoic acid and cyclic adenosine monophosphate 
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(AMP) induced endothelial-specific genes and a morphological transformation into a 
mature endothelial cell phenotype 205. Besides the early finding of Hatzopoulos et al., 
that isolated eEPCs can incorporate into vasculature during embryonic development 
further evidence was provided that eEPCs may allow the investigation of 
angiogenesis in the early and mature vascular development. The local and systemic 
administration of eEPCs in rabbits and mice, respectively, led to a measurable 
increase in neovasularization and improved tissue recovery 206. In these experimental 
hindlimb- and myocardial-ischemia models, eEPCs were shown to be temporarily 
associated with the host blood vessels and vascular structure and therefore strongly 
induced vascular growth within the ischemic tissue 206. The same study provided first 
evidence that these effects may be due to a variety of EPC-derived angiogenic 
factors. mRNA expression of relevant angiogenic-related factors such as VEGF-A 
and B, PDGFA associated protein 1 and angiogenin has been shown. Besides the 
angiogenic factors, also chemokines and cytokines related to angiogenesis are 
expressed on mRNA level by eEPCs, like CXCL1, CX3CL1, and most prominently 
MIF. These data show that eEPCs are an abundant source of proteins which regulate 
endothelial growth and organ development 206. 
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II. Aim of the study 
 
This work aimed at getting insight into the process of ischemic tissue revitalization 
through angiogenesis. As angiogenesis is a highly complex process, my thesis was 
divided into two parts. 
The first goal of my thesis was to evaluate the angiogenic potential of MIF in 
comparison with VEGF, CXCL12 and CXCL1, and in conjunction with the application 
of embryonic endothelial progenitor cells under normoxic versus hypoxic conditions. 
A particular focus was laid on the investigation of the potential angiogenic activities of 
MIF, as this protein has only recently been recognized as an angiogenic factor with 
chemokine-like functions and as it shares two of its receptors with CXCL1 and 
CXCL12. Therefore, the following questions were addressed: 
•  Do eEPCs and EPCs show similar phenotypical characteristics? 
•  Are angiogenic chemokines and factors secreted by eEPCs and EPCs 
under normoxia and if so, does the level of secretion change under 
hypoxic conditions? 
•  How does the adhesion, chemoattraction and transmigration behavior of 
eEPCs and EPCs change due to chemokine/cytokine stimulation under 
hypoxic conditions compared to normoxia in vitro? How does MIF in 
particular behave in such EPC recruitment processes? 
•  Are eEPCs and EPCs able to form tube-like structures in vitro? And if so, 
how do different chemokines influence their tube formation potential 
under normoxia and hypoxia? How does MIF in particular compared to 
the angiogenic potential of classical angiogenic factors such as VEGF? 
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•  Are the different chemokines/cytokines able to induce the formation of 
tube-like structure in vivo? 
•  Are eEPCs able to form tube-like structures in combination with the 
different chemokines/cytokines in vivo? 
The second goal of my thesis was to investigate the role of MIF and its receptor 
CXCR2 in the mouse model of myocardial ischemia/reperfusion. Thus, the effect of 
endogenous MIF on neo-angiogenesis via CXCR2 was evaluated. The following 
questions were addressed: 
•  How does MIF antibody treatment influence the recovery of bone 
marrow-reconstituted mice (wt+wt BM, wt+Cxcr2-/- BM, Cxcr2-/-+wt BM) 
after myocardial I/R? 
•  Is there a functional change of the hearts between the three different 
groups 1 day after myocardial I/R? 
•  Do the hemodynamic parameters change between the three different 
groups 1 week after myocardial I/R? 
•  What impact do MIF and the knockout of CXCR2 have on inflammatory 
cell recruitment and neo-angiogenesis in vivo? 
The therapeutic potential of MIF in angiogenesis is highlighted in both parts of my 
thesis as it seems to be a novel promising therapeutic target in myocardial 
regeneration and neoangiogenesis. 
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III. Materials and Methods 
 
All solutions were prepared with double-distilled water (Heraeus Destamat, Heraeus, 
Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, MA). 
Reagents were from Fluka (Buchs, Switzerland), Sigma-Aldrich (Deisenhofen, 
Germany), or Roth (Karlsruhe, Germany), if not stated otherwise. 
III.1. General Equipment 
Tabel 2 List of the general equipment used and their suppliers 
Equipment Manufacturer 
Autoclave Systec 2540EL (Systec, Wettenberg, Germany) 
Balance Analytical Plus (Ohaus, Pine Brook, NJ, USA) 
Centrifuges 
Eppendorf 5417C (Eppendorf, Hamburg, Germany), 
Heraeus 
Labofuge 400 and Heraeus Multifuge 3 S-R (Heraeus, 
Osterode, Germany) 
Echocardiograph Vevo 770 (Visual Sonics, Toronto, Canada) 
Flow cytometers FACS Canto II (BD Biosciences, San Jose, CA, USA) 
Fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
Incubator Hera Cell 240 (Thermoscientific, Bonn, Germany) 
Laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
Langendorff apparatus 
UP-100 base (Hugo Sachs Elektronik-Harvard 
Apparatus, March-Hugstetten, Germany) 
Microscopes 
Leica DMLB (Leica, Wetzlar, Germany) 
Olympus IX81 (Olympus, Hamburg, Germany) 
Microtome Cut 6062 (SLEE Mainz, Germany) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
Rodent respirator Harvard Apparatus (March-Hugstetten, Germany) 
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III.2. Miscellaneous Reagents 
Tabel 3 List od the miscellaneous  reagents used and their suppliers 
Reagents Manufacturer 
Accutase PAA (Pasching, Austria) 
BD Matrigel™ BD (San Jose, CA, USA) 
Bovine serum albumin (BSA) Serva (Heidelberg, Germany) 
Calcein Invitrogen (Carlsbad, CA, USA) 
DAPI Vector (Burlingame, CA, USA) 
Eosin G-Solution 0,5% Roth (Karlsruhe, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Böhringer Mannheim (Indianapolis, USA) 
Fetal calf serum (FCS) PAA (Pasching, Austria) 
Fibronectin Biochrom (berlin, Germany) 
Formalin Roth (Karlsruhe, Germany) 
Gentamycin  Gibco (Darmstadt, Germany) 
HBSS Gibco (Darmstadt, Germany) 
Hematoxylin coatified Applichem (Darmstadt, Germany) 
Hepes Gibco (Darmstadt, Germany) 
Human serum Innovative Research (Novi, USA) 
Ketamin CEVA (Düsseldorf, Germany) 
L-Glutamine PAA (Pasching, Austria) 
Lympholyte®-Mammal Cedarline (Burlington, NC, USA) 
Mouse serum Sigma-Aldrich ( St. Louis, USA) 
Non-essential amino acids (NEAA) PAA (Pasching, Austria) 
PBS PAA (Pasching, Austria) 
Penicillin PAA (Pasching, Austria) 
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Rabbit serum Sigma-Aldrich (St. Louis, USA) 
Streptavidin PAA (Pasching, Austria) 
Xylazin Medistar (Hannover, Germany) 
β-mercapthoethanol Sigma-Aldrich (St. Louis, USA) 
DMEM liquid high glucose Invitrogen (Carlsbad, CA, USA) 
DMEM Ham´s F-12 PAA (Pasching, Austria) 
Microvascular endothelial growth 
medium MV2 
Promocell (Heidelberg, Germany) 
Paraformaldehyde Sigma-Aldrich (St. Louis, USA) 
Gomori’s 1-step trichrome stain Sigma-Aldrich (St. Louis, USA) 
Naphthol AS-D Chloroacetate Kit Sigma-Aldrich (St. Louis, USA) 
III.3. Buffer/Solution/Media preparation 
Tabel 4 Preparation of buffers, solutions and media 
Buffer/Solution/Media Composition 
DMEM liquid high glucose 25 mM Hepes, 20% FBS, 1% L-
Glutamine, 1% pen/strep , 1% NEAA, β-
mercapthoethanol (3,5 µl/500ml) 
DMEM Ham´s F-12 5% FBS, gentamycin (1:1000) 
Microvascular-endothelial-growth 
medium MV2 
MV2 supplement, gentamycin (1:1000) 
Hank`s complete solution 1 x HBSS, 0.1% BSA and 5 mM EDTA  
FACS staining buffer PBS, 2% mouse serum, 2% rabbit serum, 
2% human serum, 2% BSA 
PFA (paraformaldehyde) 4% Paraformaldehyde, 5% Sucrose, 0.02 
M EDTA, pH 7.4 
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III.4. Cytokines and Recombinant Proteins 
Tabel 5 List od used cytokines and recombinant proteins and their suppliers 
Name Maufacturer 
rmMIF Bernhagen Lab, RWTH Aachen, Germany 
rmCXCL1 PeproTech, Hamburg, Germany 
rmCXCL12 PeproTech, Hamburg, Germany 
rmVEGF165 PeproTech, Hamburg, Germany 
III.5. Antibodies 
Primary Antibodies 
Tabel 6 List of used primary antibodies and their suppliers 
Name mAb Clone Manufacturer 
CD3 Rat anti-mouse KT3 Serotec 
CD31 Goat anti-mouse M-20 Santa Cruz 
Mac2 Rat anti-mouse M3/38 Cedalane 
α-SMA Mouse anti-human 1A4 DAKO 
F4/80 Rat anti-mouse CI:A3-1 Serotec 
 
Directly conjugated antibodies 
Tabel 7 List of used directly conjugated antibodies and their suppliers 
Name mAb Clone Manufacturer 
VEGFR2-PE Rat anti-mouse AVAS 12α1 BD 
CXCR4-PE Rat anti-mouse 2B11/CXCR4 BD  
CXCR2-PE Rat anti-mouse 242216 R&D 
CD31-PE-Cy7 Rat anti-mouse 390 eBioscience 
CD74-FITC Rat anti-mouse In-1 BD 
CD11b FITC Rat anti-mouse M1/70 eBioscience  
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Secondary Antibodies 
Tabel 8 List of used secondary antibodies and their suppliers 
Name Ab Manufacturer 
Goat IgG, Cy3-conjugated Rabbit anti-goat-IgG Jackson ImmunoResearch 
Goat IgG, FITC-conjugated Goat anti-rat-IgG  Jackson ImmunoResearch 
Goat IgG, FITC-conjugated Goat anti-mouse-IgG Jackson ImmunoResearch 
Rat IgG, Cy3-conjugated Donkey anti-rat-IgG Jackson ImmunoResearch 
 
Neutralizing Antibodies 
Tabel 9 List of used neutralizing antibodies and their suppliers 
Name mAb Clone Manufacturer 
CXCL1 Rat anti-mouse 124014 R&D  
CXCL12 Mouse anti-human/mouse 79014 R&D 
MIF Mouse anti-mouse NIH/111D.9 Bernhagen Lab 
VEGF164 Goat anti-mouse - R&D 
 
Isotype control 
Tabel 10 List of used isotype control and their supplier 
Name  mAB Manufaturer 
IgG2A Rat R&D 
IgG1 Rat AbD Serotec 
IgG Mouse Santa Cruz 
III.6. Mice 
Wild-type C57/BL/6J mice and BALB/c mice were purchased at Janvier, Belgium or 
Charles River, England. Cxcr2-/- mice were obtained from Jackson Lab (USA) and 
Materials and Methods 
 41
bred at the Bernhagen Lab (Insitute of Laboratory Animal Science, RWTH Aachen, 
Germany). 
Tabel 11 List of used mouse strains including the gene name, abbreviation, backgrounf and description of 
the targetgene 
Gene Name Abbreviation Background Description of 
transgene 
Wildtype wt C57/BL/6J None 
Chemokine 
(CXC-motif) 
receptor 2 
CXCR2 BALB/c Targeted mutation 
(knock-out) 
BALB/c/AnNCrl BALB/c BALB/c None 
III.7. Cell Culture 
Cell culture maintenance and experiments were performed under sterile conditions in 
a laminar flowhood. All cells were cultured in a CO2-incubator at 37°C and 5% CO2. 
For hypoxic experiments, eEPCs were incubated at 37°C in a 2% O2 and 5% CO2 
incubator (Hera Cell 240, Thermoscientific) for 48h before being used for any hypoxia 
experiments. During hypoxic experiment incubation periods the cells were placed into 
the hypoxic incubator (Innova CO-48, New Brunswick). 
III.7.1. Isolation and culture conditions of eEPCs, EPCs and SVEC 
Embryonic EPCs were kindly provided by Dr. Kupatt (Medizinische Klinik u. Poliklinik 
I, Munich) and were cultured in 77% Dulbecco's modified eagle's medium/liquid high 
glucose media. 
Endothelial progenitor cells (EPC) were derived from spleens of 6-8 weeks old male 
C57/BL6/6J mice. After euthanasia under isofluran aerosol, the spleens were 
removed and the cell isolation was performed under a laminar flow hood. The spleen 
tissue was minced by a syringe plunger and filtered through a mesh ring (30µm). The 
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cellsuspension was loaded on top of Lympholyte®-Mammal and density gradient 
centrifugation (2000 rpm, 20 min) separated the mononuclear cells from erythrocytes, 
dead cells and tissue debris. After washing the mononuclear cell fractions with PBS, 
it was suspended in microvascular endothelial growth medium MV2, containing 
gentamycin (1:1000) and seeded onto a fibronectin-coated 6-well plate. After 4 days 
of culturing, medium was changed and nonadherent cells were removed. At day 14, 
adherent cells were harvested using Accutase, counted and used for further 
experiments. These animal studies were approved by the local authorities and 
complied with German animal protection law. 
Simian virus 40-immortalized murine endothelial cells (SVECs) were cultured in 
Dulbecco's modified eagle's medium/Ham´s F-12 medium at 37°C in a 5% CO2 
incubator. 
III.8. Fluorescence Based Assays 
III.8.1. Flow Cytometry 
Fluorescence activated cell sorting (FACS) is used to analyze cells according to their 
size, granularity and protein expression. In a buffer stream, one cell at a time passes 
by an argon laser, which excites fluorescently labeled cells. Measurements of the 
size (forward scatter) and granularity (sideward scatter) are independent from the 
fluorescence signal. 
For the flow cytometric analysis, the cells (1x106) were stained for 20 min on ice 
using the corresponding antibodies (CD11b-FITC (1:100), VEGFR2-PE (1:100), 
CD31–PE-Cy7 (1:100), CD74-FITC (1:100), CXCR2-PE (1:20), CXCR4-PE (1:100)) 
diluted in FACS staining buffer. The cells were washed in Hank`s complete solution 
and analyzed using a FACS Canto II flow cytometer and FLOW JO Software. Non-
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stained cells served as controls. The results are displayed as diagrams showing the 
change in mean fluorescence intensity. 
III.8.2. Enzyme-linked immunosorbent assay (ELISA) 
VEGF, CXCL12 and CXCL1 levels in the supernatants of approximately 2x106 
cultured eEPCs under normoxic (20% O2) and hypoxic (2% O2) conditions were 
determined using DuoSet ELISA Development Kits by R&D Systems (mouse VEGF 
DY493, mouse CXCL12/SDF-1 DY460, mouse CXCL1/KC DY453) in accordance 
with the manufacturer’s protocol. Briefly, a 96-well plate is coated with a purified 
antibody specific for the antigen of interest. All samples and standards are added, 
and any antigen present binds to the capture antibody. After washing the detecting 
antibody is added, and binds to the antigen. The next step is the addition of an 
enzyme-linked secondary antibody, which binds to the detecting antibody. After 
adding the substrate the enzyme reaction yields a blue product that turns yellow 
when the stop solution is included. The intensity of the colour measured is in 
proportion to the amount of antigen bound in the initial step. The sample values are 
then read off a standard curve. 
MIF levels were detected essentially as described previously 207 using capture 
antibody MAB289 and detection antibody BAF289 from R&D Systems. 
For evaluating the secretion of angiogenic factors under hypoxic and normoxic 
conditions, eEPCs or EPCs were incubated overnight in 12 well plates under 
normoxic conditions. For determining the secretion under hypoxia, the normoxic 
media was exchanged by hypoxic media at t=0 and kept under these condition for 
variable periods of time (one plate for each period of time). Prior to hypoxic medium 
exchange, a 1m l aliquot of the supernatant medium was retrieved and saved at  
-20oC. Concentrations of angiogenic factors were determined by collecting 1m l 
aliquots at 1, 3, 6, 12, 24 and 48 h and performing the ELISAs. 
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III.8.3. Histochemistry and Immunhistochemistry 
Serial sections (10 section/mouse) of the Matrigel plugs and were used for stainings 
to analyze blood vessel formation (Hematoxylin and Eosin) and content of 
lymphocytes (CD3), macrophages (Mac2), vessels (CD31), and myofibroblasts (α-
smooth muscle actin). Vessels and cells were counted in the total Matrigel area and 
expressed as number of tubes/ field or percentage of positive cells of total number of 
cells, respectively. 
For the evaluation of MI size, serial sections (10-12 sections/mouse, 400 µm apart, 
up to the mitral valve) were stained with Gomori’s 1-step trichrome stain. The 
infarcted area was determined in all sections using Diskus software (Hilgers) and 
expressed as percentage of total left ventricular volume. 
Serial sections (3 sections/mouse, 400 µm apart) were stained to analyze infarcted 
areas for the content of neutrophils (specific esterase), macrophages (F4/80), 
lymphocytes (CD3), vessels (CD31), and myofibroblasts (α-smooth muscle actin). 
Cells or vessels were counted in 6 different fields per section and expressed as cells 
or vessels/mm². 
III.9. Functional Assays 
III.9.1. Static cell-adhesion assay 
Static adhesion assay was performed under normoxic and hypoxic conditions using a 
96-well plate. For an endothelial monolayer, 10.000 SVECs were placed in each well 
for 24 h incubated at 37°C in a 20% O2 and 5% CO2 incubator for normoxia or in a 
2% O2 and 5% CO2 incubator for hypoxia. Either neutralizing antibodies (10 µg/ml 
anti-mouse VEGF antibody, 10µg/ml anti-human/mouse CXCL12 antibody, 10 µg/ml 
anti-mouse CXCL1 antibody, 10 µg/ml anti-MIF), chemokines/cytokines (50 ng/ml 
rmVEGF165, 50 ng/ml rmCXCL12, 50 ng/ml rmCXCL1, 50 ng/ml MIF) or isotype 
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controls (10 µg/ml IgG, 10 µg/ml IgG1, 10 µg/ml IgG2A) were added to medium 
containing calcein (1 µg/ml) labelled eEPCs (20,000 per well). After incubating for 
16h at 37°C in a 5%CO2 incubator, the unattached cells were removed by washing 
the cells with PBS twice. Adherence of eEPCs on the endothelial layer was analyzed 
by multiple fluorescence top reading (excitation 480nm, emission 520nm) with 
TECAN® i-control reader and i-control software. For the statistical analysis, the 
controls were set to value 1 and the experimental groups were normalized to 1. 
III.9.2. Chemotaxis 
Chemotaxis assays were performed in 24-well cell culture chambers with BD 
Falcon™ HTS FluoroBlok™ 3.0 µm coloured PET membrane inserts. eEPCs and 
EPCs were labelled with calcein (1 µg/ml) for 30 min, washed in PBS and 
resuspended in microvascular endothelial growth medium MV2 and DMEM/liquid 
high glucose medium containing 0.5% BSA, respectively. 100 µl of the cell 
suspension (20.000 cells/well) was transferred into the membrane inserts. The 
culture chambers contained 600 µl assay medium containing different 
chemoattractants, as 50 ng/ml rmVEGF165, 50 ng/ml rmCXCL12, 50 ng/ml rmCXCL1, 
or 50 ng/ml MIF. The cells were allowed to migrate for 2 h. Migrated cells were 
quantified by staining the cells on the bottom side of the membrane filters with DAPI 
and counting them using a fluorescence microscope. For the statistical analysis, the 
controls were set to value 1 and the experimental groups were normalized to 1. 
III.9.3. Transmigration 
Transmigration assays were performed in 24-well cell culture chamber with BD 
Falcon™ HTS FluoroBlok™ 3.0 µm coloured PET membrane inserts. Brd-U marked 
SVECs were placed in fibronectin-coated inserts with 100µl DMEM/Ham´s F-12 
medium for 24 h to allow them to form an endothelial monolayer on the surface of the 
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membrane. Afterwards, the inserts were placed into wells of a 24-well plate 
containing 600 µl assay medium enriched with either 50 ng/ml rmVEGF165, 50 ng/ml 
rmCXCL12, 50 ng/ml rmCXCL1, or 50 ng/ml rmMIF. Calcein-labelled eEPCs or 
EPCS were suspended in microvascular endothelial growth medium MV2 and 
DMEM/liquid high glucose medium containing 0.5% BSA, respectively. 20.000 cells/ 
well were applied on top of the insert filters. After 2 h at 37°C, transmigrated cells on 
the bottom side of the filter were stained with DAPI and counted using a fluorescence 
microscope. For the statistical analysis, the controls were set to value 1 and the 
experimental groups were normalized to 1. 
III.9.4. Matrigel assay in vitro 
BD Matrigel™ Basement Membrane Matrix was thawed overnight at 4°C. The assays 
were performed in 24-well cell culture plates. 300 µl of matrigel were placed in each 
well and allowed to polymerize at 37°C for 30 min. A cellsuspension of eEPCs or 
EPCs in assay medium was seeded in a density of 1x105 cells/ml/well. Additionally, 
SVECs were added to each well in a density of 3x104 cells/ml/well. The cells were 
stimulated either by 50 ng/ml rmVEGF165, 50 ng/ml rmCXCL12, 50 ng/ml rmCXCL1, 
or 50 ng/ml MIF. After incubating the cells at 37°C for 24 h, tube formation ability was 
quantified by counting the total number of tube-like structures in 5 random 
microscopic fields. 
III.10. Animal Models 
III.10.1. Matrigel assay in vivo 
Matrigel (500 µl per mouse) containing different chemokines/cytokines (50 ng/ml 
rmVEGF165, 50 ng/ml rmCXCL12, 50 ng/ml rmCXCL1, or 50 ng/ml MIF or calcein 
(1µg/ml) labelled eEPCs with the above mentioned chemokines/cytokines, was 
subcutaneously transplanted into the neck of 8 week old male C57BL6/6J mice        
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(5 mice per group) after anesthesai with Ketamin (100 mg/kg) and Xylazin (10 
mg/kg). The Matrigel-mixture solidified to form a plug upon implantation. After 7 days, 
the mice were euthanized with isofluran aerosol and the Matrigel plugs were 
removed. Each Matrigel-plug was first fixed in 10%-buffered formalin for 24 h, then 
dehydrated and finally embedded in paraffin. The Matrigel plugs were cut into 5 µm 
sections and were used for further immunohistochemistry analysis. Animal studies 
were approved by the local authorities and complied with German animal protection 
law. 
III.10.2. Bone marrow transplantation 
To assess a contribution of CXCR2 to regeneration of myocardial infarction, BALB/c 
or Cxcr2-/- mice were irradiated and reconstituted with BALB/c or Cxcr2-/- bone 
marrow. For bone marrow transplantations, femurs and tibias were aseptically 
removed from donor BALB/c and Cxcr2-/- mice. Bone marrow cavities were flushed 
and single cell suspensions prepared. Donor cells (2×106) were administered by tail 
vein injection into the recipient mice 24 h after an ablative dose of whole-body 
irradiation (2x6 Grays (Gy)). After 6 weeks of recovery, mice were subjected to I/R. 
One day or one week after I/R, the hearts were harvested and used for further 
analysis. 
The bone marrow (BM) transplantated mice were split into three different groups. For 
the first group, BALB/c wildtype mice (wt) were reconstituted with BALB/c wildtype 
BM (wt BM). In the second group BALB/c wildtype mice (wt) were reconstituted with 
Cxcr2-/- bone marrow (Cxcr2-/- BM). Thirdly, Cxcr2-/- knockout mice (Cxcr2-/-) were 
reconstitued with BALB/c wildtype bone marrow (wt BM). Each of these groups was 
further divided in two subgroups, whereas one subgroup was treated with an anti-MIF 
antibody and the second subgroup was treated with an isotype control. Table 11 
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shows all used animal groups with the according antibody treatment and the 
abbreviation for each experimental group. 
Tabel 12 List of the different bone marrow transplantations, the anti-MIF antibody treatment and the 
abbreviation for each group used in the text. 
Group 
Name 
Bone marrow 
transplantation 
Anti-MIF antibody 
treatment (100 µg/week ) 
Abbreviation used in 
the text 
MIF1 wt+wt BM - wt/wt BM 
 wt+wt BM + wt/wt BM anti-MIF 
MIF2 wt+Cxcr2-/- BM - wt/ Cxcr2 BM 
 wt+ Cxcr2-/- BM + wt/ Cxcr2 BM anti-MIF 
MIF3 Cxcr2-/-+wt BM - Cxcr2/wt BM 
 Cxcr2-/-+wt BM + Cxcr2/wt BM anti-MIF 
 
III.10.3. Murine model of myocardial ischemia/reperfusion (I/R) 
The bone marrow transplanted mice, described in III.4.2, underwent coronary 
occlusion and reperfusion. Briefly, mice were intubated under general anesthesia 
(100 mg/kg Ketamine, 10 mg/kg Xylazine, ip) and positive pressure ventilated with 
oxygen and 0.2% isofluran using a rodent respirator. Hearts were exposed by left 
thoracotomy and MI was produced by suture occlusion of the left anterior descending 
artery (LAD) over a silicon tube. After 40 min of ischemia (I), the tube and suture 
were removed to permit reperfusion (R). The muscle layer and skin incision were 
closed with a silk suture. All animal experiments and study protocols were approved 
by local authorities, complying with German animal protection laws. 
III.10.4. Echocardiography 
Two-dimensional and M-mode echocardiographic measurements (Vevo 770, Visual 
Sonics, Toronto, Canada) were performed before (basal) and one day after induction 
of myocardial I/R. Mice were anesthetized with 1.5% isoflurane via mask and placed 
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in supine position on a warming pad. Two different parameters were recorded and 
analyzed. First, the ejection fraction (Ef), which is the fraction of blood pumped out of 
the right ventricle of the heart to the lungs and the left ventricle of the heart to the 
systemic circualtion with each heart beat or cardiac cycle. It can be calculated as the 
difference between end-diastolic volume (EDV) and end-systolic volume (ESV) 
divided by the EDV. Secondly, the cardiac output (CO), which is the volume of blood 
being pumped by the heart in particular by a left or right ventricle in the time interval 
of one minute. Its value is calculated by multipliing the SV with the heart rate (HR). 
 
Figure 7 Summary oft he formulas for calculating the ejection fraction (Ef) and the cardiac output ((CO)) 
 
III.10.5. Langendorff perfusion 
Langendorff perfusion allows the examination of cardiac contractile strength, heart 
rate and vascular effects without the neuronal and hormonal complications of an 
intact animal model. In the Langendorff preparation, the aorta is cannulated and the 
heart is perfused in a reversed fashion, usually with a nutrient rich, oxygenated 
solution. The pressure of the solution causes the aortic valve to shut and the 
perfusate is then forced into the ostium and into the coronary vessels. 
After one week, mice were anesthetized with Ketamin (100 mg/kg) and Xylazin (10 
mg/kg) and heart function was analyzed using a Langendorff apparatus and Isoheart 
software under constant perfusion pressure (100 mmHg) and electrical stimulation to 
assure constant heart rates ((600/min constant heart rate). Coronary flow, left 
ventricular developed pressure (LVDP), increase (dP/dtmax) and decrease 
(dP/dtmin) in LV pressure were measured without and with dobutamine. Finally, 
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hearts were fixed with 10% formalin, paraffin embedded, cut into 5µm serial slices 
and used for further analysis. 
III.11. Statistical Analysis 
Data represent mean±SEM. Statistical analysis was performed with Prism 4 software 
(Graph Pad) using unpaired Student-t test or 1-way ANOVA followed by Newmann-
Keuls post test, as appropriate. P-values <0.05 were considered significant. 
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IV. Results 
IV.1. Angiogenic potential of MIF and eEPCs in vitro and in vivo 
IV.1.1. Characterization of EPCs and upregulation of chemokine 
receptor expression and angiogenic chemokine/mediator secretion 
in EPCs 
First the EPCs used in this study were characterized. As shown by flow cytometry, 
isolated primary murine EPC (EPCs) as well as eEPCs were positive for the 
mononuclear- (CD11b) and endothelial-specific markers CD31 and VEGFR-2 (Figure 
8 A). Moreover, EPCs expressed substantial levels of CXCR2 and CXCR4 on their 
surface. This confirmed prior data showing that CXCR2 and CXCR4 can serve as 
markers for EPCs. In contrast, resting eEPCs did not exhibit any appreciable CXCR2 
or CXCR4 surface expression (Figure 8 A). However, exposing eEPCs to hypoxic 
conditions (2% O2) for 24 h or 48 h led to a marked upregulation of the surface 
expression of CXCR2 and CXCR4, whereas the third MIF receptor CD74 was neither 
detected on EPCs (data not shown) nor on resting or hypoxia-stimulated eEPCs 
(Figure 8 B). 
Embryonic EPCs have been shown to carry angiogenic mediators 206, but the effect 
of hypoxic gradients on angiogenic factor/chemokine expression by EPCs as it may 
occur in ischemic EPC recruitment situations in vivo is unknown. eEPCs were 
challenged with hypoxic conditions over a time course of 48 h and analyzed the 
levels of secreted MIF, CXCL1, CXCL12, and VEGF by ELISA at different time 
intervals upon hypoxia (Figure 8 C). MIF was abundantly secreted and the secretion 
profile followed a biphasic curve with maxima at 3 and 48 h which is reminiscent of 
the bimodal MIF secretion profile of hypoxically treated endothelial cells 167.  
 
Results 
 52
 
Figure 8 Characterization of EPCs and upregulation of chemokine receptor expression and angiogenic 
chemokine/mediator secretion in EPCs. (A) Characterization of the EPCs used in this study. Flow cytometric 
analysis for CD11b, CD31, VEGFR-2, CXCR2, and CXCR4 surface expression on EPCs and eEPCs 
(fluorescence intensity of control IgG staining shown in shaded grey). (B) Effect of hypoxic treatment (2% O2) 
on the surface expression levels of CXCR2, CXCR4 and CD74 on eEPCs. Normoxic conditions (20% O2) 
(green) were compared with a 24 h (blue) and 48 h (red) hypoxic treatment and isotype control IgG staining 
(black). (C) The secretion of angiogenic EPC-derived factors/chemokines is upregulated by hypoxia. Secretion 
of MIF, VEGF, CXCL12, and CXCL1 from eEPCs at different time points following hypoxic stimulation was 
measured by ELISAs (*p<0.05 vs. control, n=3). 
 
EPC 
eEPC 
eEPC 
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The secretion of the other three proteins was monophasic. CXCL1 levels peaked one 
hour after hypoxia and then declined, whereas CXCL12 secretion was only 
detectable in a narrow window of 3-6 h. In contrast, VEGF production increased 
continuously over the entire time course, but significant secretion levels were not 
detected until 6 h after hypoxic exposure (Figure 1C, *p<0.05 vs. control). 
IV.1.2. Enhancement of EPC recruitment by angiogenic 
factors/chemokines: prominent role for MIF and VEGF 
EPCs recruited into ischemic/hypoxic tissues are subject to chemotactic migration, 
adhesion and transmigration processes. As shown above, EPCs also express and 
secrete angiogenic factors and chemokines upon hypoxic challenge. Thus, the 
effects of MIF, CXCL1, CXCL12, and VEGF on EPC and eEPC adhesion, 
chemotaxis, and transmigration in vitro were compared. Adhesion experiments of 
EPCs or eEPCs on SVEC monolayers showed that MIF, VEGF, CXCL12, and 
CXCL1 all promoted the static adhesion of eEPC by a small, yet significant, margin 
(Figure 9 A). This effect did not differ between hypoxic and normoxic conditions 
(compare Figure 9 A and B). 
More strikingly, all factors/chemokines markedly and significantly enhanced EPC 
chemotaxis (Figure 9 C), but only MIF and CXCL1 also triggered the transmigration 
capacity of the EPCs through an endothelial layer (Figure 9 E). Whereas for EPCs 
chemotaxis and transmigration was only studied under normoxic conditions, eEPC 
chemotaxis and transmigration was compared between normoxic and hypoxic 
conditions. MIF had the most prominent effect on both chemotaxis and transmigration 
of eEPCs, with chemotactic and transmigration indices of >6-fold and >4-fold 
observed, respectively; these effects were significantly increased under hypoxic 
conditions at which MIF increased eEPC chemotaxis by 10-fold and transmigration 
by 8-fold. 
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Figure 9 Enhancement of EPC recruitment by angiogenic factors/chemokines: prominent role for MIF 
and VEGF. (A-B) Static adhesion of eEPCs on an endothelial layer under normoxic (A) and hypoxic (B) 
conditions (*p<0.05 vs. isotype control, n=3). (C) Chemotactic migration of calcein-labeled EPCs under 
normoxic conditions (*p<0.05 vs. control, n=3). (D) Chemotactic migration of calcein-labeled eEPCs under 
normoxic (black bars) and hypoxic (white bars) conditions towards MIF, VEGF, CXCL12, and CXCL1 
(*p<0.05 vs. control, 
§
p<0.05 vs. normoxia, 
#
p<0.05 vs. MIF under hypoxia; n=3). (E) Transmigration of EPCs 
through an endothelial layer induced by MIF, VEGF, CXCL12 and CXCL1 (*p<0.05 vs. control, n=3). (F) 
Transmigration experiment as in (E) except that eEPCs were analyzed and normoxic versus hypoxic conditions 
compared for all chemokines/factors (*p<0.05 vs. control, 
§
p<0.05 vs. normoxia, 
#
p<0.05 vs. MIF in hypoxia; 
n=3). 
 
Enhancement of chemotaxis and transmigration by the other chemokines/factors 
appeared somewhat weaker (2-3-fold under normoxia and 3-5-fold under hypoxia), 
but was also significant for most conditions, with VEGF and CXCL12 exerting the 
strongest chemotactic/transmigration effects on hypoxically challenged eEPCs. Thus, 
MIF appeared to be a highly potent angiogenic recruitment factor when compared to 
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VEGF, CXCL12, and CXCL1, both under normoxic and hypoxic conditions, and in 
particular with respect to the embryonic EPCs. 
IV.1.3. Comparison of the tube formation potential of the angiogenic 
factors/chemokines in vitro and in vivo 
To study the role of the pro-angiogenic factors in tube formation, matrigel 
experiments were performed. First, a suspension of SVECs together with EPCs or 
eEPCs was added on a matrigel base and incubated for 24 h with the various 
angiogenic factors. All tested factors significantly improved EPC integration and tube 
formation on matrigel in vitro (Figure 10 A). 
EPC eEPC
 
Figure 10 Comparison of the tube formation potential of the angiogenic factors/chemokines in vitro. Tube 
formation was evaluated in Matrigel matrices containing (e)EPCs/SVECs cell suspensions. (A) Number of 
formed tubes in vitro by EPCs under normoxic conditions after 24 h (*p<0.05 vs. control; n=6). (B) Embryonal 
EPC-mediated tube formation assay in vitro under normoxia versus hypoxia after stimulation with MIF, VEGF, 
CXCL12 or CXCL1 for 24 h (*p<0.05 vs. control, 
§
p<0.05 vs. normoxia, 
#
p<0.05 vs. MIF in hypoxia; n=4). (C) 
Representative images from each group (scale bare: 50 µm). 
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Tube integration of eEPCs was promoted by all three chemokines but not VEGF 
under normoxic conditions, whereas under hypoxia all factors accelerated eEPC-
mediated tube formation (Figure 10 B and C). 
In vivo tube formation in implanted matrigel plugs was assessed one week after 
implantation of angiogenic factor/chemokine-loaded matrigel plugs. Of note, only 
VEGF was able to induce tube formation in vivo under these conditions (Figure 11 A-
B), suggesting its important role in angiogenesis, especially under hypoxic conditions. 
Next, the cell types recruited into the matrigel plug were analyzed by 
immunohistological staining. Recruited cells in all groups (including the control group) 
comprised Mac2-positive macrophages and SMA-positive cells, as well as some 
CD3-positive lymphocytes (Figure 11 C). Interestingly, CD31-positive cells, even 
though at low numbers, were only detectable in the MIF group (Figure 11 C). 
 
Figure 11 Comparison of the tube formation potential of the angiogenic factors/chemokines in vivo.  (A) In 
vivo tube formation in matrigel plugs conzaining MIF, VEGF, CXCL12 or CXCL1 analyzed after 1 week 
(*p<0.05 vs. control, n=5) ). (B) Representative H&E stains from (A) (scale bar 400 µm). (C) Specific 
immunohistochemistry stainings for macrophages (Mac2), lymphocytes (CD3) and endothelial cells (CD31) as 
detected in MIF-containing Matrigel plugs (scale bar 25 µm). 
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IV.1.4. Tube formation and differentiation of eEPC in matrigel in vivo 
To directly study the differentiation capacity of eEPCs under hypoxic conditions in 
vivo, matrigel plugs containing mixtures of eEPCs and the different angiogenic 
factors/chemokines or control buffer were transplanted subcutaneously into mice. 
After 7 days, the tube formation rate in all groups was 10-times higher as in matrigel 
plugs without eEPCs, suggesting a decisive role for the progenitor cells in initiating 
and sustaining vessel formation (Figure 11 A und 12 A). In addition, the CXCL12 
group showed a significantly increased number of tubes compared to all other eEPC-
containing groups, implying an important role for this chemokine in the later phases 
of angiogenesis (Figure 12 A). 
Next, to find out which cell types had been preferentially recruited into the matrigel 
plugs and/or differentiation processes towards what cell type had been favored under 
the influence of the various angiogenic factors/chemokines. Thus, the CD31+ and 
smooth muscle cell (SMC) content in the matrigel implants was analyzed. As 
revealed by immunohistochemistry, only 2-3% of the cells were local CD31+ cells. 
Despite this overall low abundance of CD31+ cells, we observed a significant 
differentiation of recruited cells towards an endothelial phenotype upon MIF, but not 
VEGF, CXCL12, or CXCL1 stimulation (Figure 12 B). More importantly, MIF also was 
the only factor which promoted the differentiation towards SMCs, a cell type which is 
decisive in the collateralization of larger vessels and which was abundantly found in 
the newly formed vessels (Figure 12 B). Surprisingly, CXCL12 did not promote 
differentiation towards SMCs, but even inhibited this differentiation process, although 
it is known to play a central role in the recruitment of SMC progenitors 208. 
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Figure 12 Tube formation and differentiation of eEPCs in Matrigel in vivo. (A) In vivo tube formation in 
transplanted Matrigel plugs containing both eEPCs and either MIF, VEGF, CXCL12, or CXCL1 analyzed after 1 
week and representative H&E stains (scale bar 400 µm). Percentage of CD31- (B) and SMA- (C) positive cells 
as detected in the Matrigel plug sections (*p<0.05 vs. control; n=6; scale bar 25 µm). 
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IV.2. Effect of Endogenous MIF on Neoangiogenesis in vivo via 
CXCR2 
A previous study has shown that MIF has a particular aptitude to bind the arrest 
receptor CXCR2. It was proven that MIF is involved in leukocyte recruitment in a 
more universal sense than it was thought before. Additionaly, in contrast to the 
canonical ligands CXCL8 and CXCL12, which act in a more cell-restricted manner, 
MIF promoted the recruitment of both monocytes and T cells by interacting with 
CXCR2 and CXCR4, respectively. Furthermore, an atherosclerotic plaque model in 
Apoe-/- mice has confirmed that blocking MIF (as a dual CXCR2/CXCR4 agonist), but 
not the cognate ligands CXCL1 and CXCL2, leads to a regression of pre-existing 
atherosclerotic plaques and that both macrophage and T-cell content are reduced, 
resulting in a more stable plaque phenotype 170. These data demonstrated the 
importance of MIF in the context of inflammation and atherosclerosis and was 
recognized as a target for treating inflammatory disease. 
As shown in the first part of my thesis, MIF plays also a crucial role in EPC function 
and angiogenesis. Thus, the effect of endogenous MIF on neoangiogensis in vivo via 
CXCR2 was investigated. For this purpose, myocardial I/R was induced in irradiated 
wild type mice reconstituted with wildtype or Cxcr2-/- bone marrow and Cxcr2-/- mice 
reconstituted with wild type bone marrow. The mice were treated with anti-MIF 
antibody or isotype control and heart functions, infarct size as well as the 
inflammatory response were analyzed. 
IV.2.1. Functional changes of hearts after I/R were detected by 
echocardiography 
Heart function of the mice was evaluated by echocardiography before and one day 
after myocardial I/R induction. By using the Vevo 700 software, ejection fraction (EF), 
cardiac output (CO), heart rate (BPM) and heart weight were analyzed. Figure 13 
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shows, that the EF significantly droped 1 d after I/R in the 1d wt/wt BM+anti-MIF 
group compared to 1d wt/wt BM group. The same trend (drop of EF after anti-MIF 
treatment compared to control at day one after I/R) was observed in the wt/Cxcr2 BM 
group. By contrast, knock out of Cxcr2 in the Cxcr2/wt transplanted mice, led to a 
significant increase of the ejection fraction one day after I/R when treated with an 
anti-MIF antibody compared to the non-treated group. The ejection fraction of the 
anti-MIF group showed even a significant augmentation compared to the basal 
values, measured before I/R induction (Figure 13). 
 
Figure 13 Ejection fraction (%) 1 d after I/R is positively changed by anti-MIF treatment in the 1 d 
Cxcr2/wt BM+anti MIF group compared to isotype control, whereas a negative change of EF in the 1 d 
wt/wt BM+anti-MIf and 1d wt/Cxr2 BM+anti-MIF compared to isotype control is observed. Heart function 
was measured by echocardiography before I/R induction and anti-MIF treatment (basal) and 1 d after I/R 
induction (1 d). After I/R the three transplanted mice groups were divided into subgroups which either received 
an anti-MIF antibody treatment (+anti-MIF) or an isotype control. (*p<0.05, 1d n=4-6) 
 
The second parameter evaluated was cardiac output. The analysis of the cardiac 
output revealed a good compensation in all studied groups (Figure 14). Remarkably, 
the transplantation of Cxcr2-/- bone marrow caused a dramatic decline of cardiac 
output 1 d after I/R which was partly reversed by anti-MIF antibody treatment (Figure 
14). 
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Figure 14 Cardiac output (%) 1 d after I/R is positively changed by anti-MIF treatment in the 1 d 
wt/Cxcr2 BM+anti MIF group compared to isotype control, whereas a negative change of CO in the 1 d 
wt/wt BM+anti-MIf and 1d Cxr2/wt BM+anti-MIF compared to isotype control is observed. Heart function 
was measured by echocardiography before I/R induction and anti-MIF treatment (basal) and 1 d after I/R 
induction (1 d). After I/R the three transplanted mice groups were divided into subgroups which either received 
an anti-MIF antibody treatment (+anti-MIF) or an isotype control. (*p<0.05, n=4-6) 
 
In table 13, 14 and 15 the mean values and the corresponding standard error of the 
mean values of EF (%), CO (ml/min), heart rate (BPM) and heart wight (mg) are 
listed. Neither the heart rate nor the heart weight was altered between the 
experimental bone marrow transplanted mice at different time points. 
Tabel 13 Summary of functional data of wt\wt BM experimental groups 1 d after myocardial I/R 
Echocardiography 
  1d 
 Basal wt/wt BM wt/wt BM wt/wt BM anti MIF 
EF (%) 65.83±1.94 56.28±3.18 43.32±4.26 
CO (ml/min) 13.66±0.69 14.25±1.12 10.87±2.30 
Heart rate 
(BPM) 
428.5±12.06 445.0±23.0 410.4±12.69 
Heart weight 
(mg) 
101.2±4.67 87.22±2.52 91.28±3.40 
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Tabel 14 Summary of function data of wt\Cxcr2 BM experimental groups 1 d after myocardial I/R 
Echocardiography 
  1d 
 Basal wt/Cxcr2 BM wt/Cxcr2 BM  wt/Cxcr2 BM anti MIF 
EF (%) 65.31±2.43 65.40±1.88 57.36±2.17 
CO (ml/min) 11.62±0.38 4.75±0.61 9.54±0.73 
Heart rate 
(BPM) 
395.3±11.24 370.8±13.84 425.4±25.78 
Heart weight 
(mg) 
93.98±3.17 67.77±4.91 102.7±9.12 
 
 
Tabel 15 Summary of function data of Cxcr2\wt BM experimental groups 1d after myocardial I/R 
Echocardiography 
  1d 
 Basal Cxcr2/wt BM Cxcr2/wt BM  Cxcr2/wt BM anti MIF 
EF (%) 42.05±2.75 47.99±2.64 62.03±2.36 
CO (ml/min) 10.99±0.89 11.81±1.54 7.78±1.29 
Heart rate 
(BPM) 
437.3±14.08 464.6±92.78 434.8±19.01 
Heart weight 
(mg) 
119.3±7.91 110.3±6.66 68.31±3.52 
 
IV.2.2. Hemodynamic changes of hearts after I/R were detected by 
Langendorff 
The haemodynamic data as left ventricular developed pressure (LVDP), maximal 
(dP/dtmax) and minimal (dP/dtmin) pressure change in the left ventrical were measured. 
Anti-MIF antibody treatment caused the LVDP to drop drastically in the wt/wt 
BM+anti-MIF and wt/Cxcr2 BM+anti-MIF groups as compared to their control groups. 
An opposite effect was observed in the Cxcr2/wt BM transplanted mice. When the 
Cxcr2/wt BM mice received the neutralizing MIF antibody, the LVDP ameliorated by 
one third, without statistical significance (Figure 15 A). Contrary and relaxation 
measurments confirmed the results. Wt/wt BM mice as well as wt/Cxcr2 mice 
significantly deteriorate their dP/dtmax and dP/dtmin when the anti-MIF antibody was 
applied. In opposition to these findings, the anit-MIF antibody administration to the 
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Cxcr2/wt BM transplanted mice again caused functional improvements regarding the 
dP/dtmax as well as the dP/dtmin (Figure 15 C,D). 
 
Figure 15 Hemodynamic parameters measured via Langendorff perfusion show functional improvements 
inLVDP, dP/dtmax and dP/dtmin, caused by anti-MIF antibody treatment 1 w after I/R in the Cxcr2/wt 
BM+anti-MIF group compared to isotype control. After I/R induction the three transplanted mice groups 
were divided into subgroups which either received an anti-MIF antibody treatment (+anti-MIF) or an isotype 
control. Heart function was measured by Langendorff heart perfusion 1 w after I/R induction and anti-MIF 
treatment (1 w). (*p<0.05, 1w n=6-10) 
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Even though, the functional enhancements of the Cxcr2/wt BM+anti-MIF mice 
compared to the wt/wt BM+anti-MIF mice and the Cxcr2/wt BM+anti-MIF mice were 
not statistically significant, they show a clear trend of efficient recovery after I/R. 
Langendorff measurements failed to reveal changes in coronary flow 1w after I/R in 
all experimental groups (Figure 15 B). 
The functional parameters, LVDP (mmHg), dP/dtmax (mmHg/s), dP/dtmin (mmHg/s), 
and coronary flow (ml/min), detected by Langendorff perfusion 1d and 1w after I/R 
are summarized as mean±SEM in table 16 and 17. 
Tabel 16 Hemodynamic parameters summarized 1d post I/R, representing mean±SEM 
Langendorff perfusion 
1d 
 
wt/wt BM 
wt/wt BM 
anti-MIF 
wt/Cxcr2 
BM 
wt/Cxcr2 
BM anti-MIF 
Cxcr2/wt 
BM 
Cxcr2/wt BM 
anti-MIF 
LVDP 
(mmHg) 
62.0±0.0 55.00±11.0 80.67±19.32 59.25±21.55 62.50±6.5 
87.5±23.50 
dP/dtmax 
(mmHg/s) 
3079±0.0 2363±472.5 4144±1150 3241±1411 3626±692.5 
4644±1157 
dP/dtmin 
(mmHg/s) 
-2591±0.0 -2029±480 -331±929.9 -2683±1217 -2739±538 
-2998±798 
Coronary 
flow 
(ml/min) 
2.10±0.0 2.20±0.0 1.675±0.77 1.90±0.90 1.90±0,20 2,10±0,20 
 
Tabel 17 Hemodynamic parameters summarized 1w post I/R, representing mean±SEM 
Langendorff perfusion 
1w 
 
wt/wt BM 
wt/wt BM 
anti-MIF 
wt/Cxcr2 
BM 
wt/Cxcr2 
BM anti-
MIF 
Cxcr2/wt 
BM 
Cxcr2/wt BM 
anti-MIF 
LVDP 
(mmHg) 
80.42±7.18 43.25±4.30 84.67±6.88 43.67±8.57 35.33±3.71 56.0±10.44 
dP/dtmax 
(mmHg/s) 
4303±334.3 2292±320.5 3736±167.5 1718±643.7 2100±301.9 2853±422.9 
dP/dtmin 
(mmHg/s) 
-2827±126 -1610±144 -2814±363 -1257±393 -1548±361 -2330±766 
Coronary 
flow 
(ml/min) 
3.23±0.41 3.35±0.29 2.60±0.45 2.65±0.05 3.06±0.67 3.20±1.00 
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IV.2.3. Myocardial I/R leads to inflammatory cell recruitment and 
neoangiogenesis 
In a next step, the mobilization and recruitment of inflammatory cells after myocardial 
I/R was analyzed, as well as their effect on neoangiogenesis. 
One day after myocardial I/R, the number of monocytes infiltrated into the infarcted 
area in the wt/wt BM group treated with anti-MIF was reduced by two-thirds as 
compared to the wt/wt BM control group. The same significant effect is observed in 
the Cxcr2/wt BM transplanted mice, even though the basal number of monocytes in 
the Cxcr2/wt BM mice is higher than in the wt/wt BM group. Only the wt mice 
receiving Cxcr2 BM, neither untreated nor anti-MIF treatment, changed the number of 
monocytes in the infarcted region (Figure 16). 
 
Figure 16 The number of monocytes infiltrated into the area of myocardial infarction 1d after I/R 
significantly droped in the wt/wt BM+anti-MIF and Cxcr2/wt BM+anti-MIF groups compared to their 
isotype controls. Hearts were isolated 1 d after I/R and cut into 5µm sections. Serial sections (3 sections/mous) 
were stained for the content of monocytes (F4/80). Cells were counted in 6 different fields/section expressed as 
cells/µm². (A) anti-MIF antibody treatment causes the number of infiltrated monocyted to drop in the wt/wt BM 
and Cxcr2/wt BM transplanted mice compared to isotype controls. (B) Representative F4/80 stains from (A) 
(*p<0.05, n=3-4, Sclae bar 25µm) 
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The number of neutrophils detected in the area of myocardial infarction did not 
significantly vary between the groups. Nevertheless, there is a tendency of more 
neutrophils in the wt/Cxcr2 BM and Cxcr2/wt BM mice compared to the wt/wt BM 
groups. (Figure 17) 
 
Figure 17 The number of neutrophils infiltrated into the area of myocardial infarction 1d after I/R did not 
change because of anti-MIF antibody treatment compared to their isotype controls. Hearts were isolated 1 
d after I/R and cut into 5µm sections. Serial sections (3 sections/mous) were stained for the content of 
neutrophils (specific esterase). Cells were counted in 6 different fields/section expressed as cells/µm² (A) anti-
MIF antibody treatment did not lead to changed numbers of infiltrated neutrophils compared to isotype controls. 
(B) Representative specific esterase stains from (A) (*p<0.05, n=3-4, Sclae bar 25µm) 
 
Besides the evaluation of the inflammatory cell content, the capability of CXCR2 
mediated neoangiogenesis was assesed. Startlingly, wt/wt BM+anti-MIF and 
wt/Cxcr2 BM+anti-MIF mice showed an increased amount of endothelial cells in the 
infarcted region, although their functional parameters were impaired compared to the 
non treated mice (Figure 15 A, C, D). On the other hand, the Cxcr2/wt BM+anti-MIF 
mice, which have shown functional improvements, seem to have a trend of reduced 
endothelial cell content versus the controls (Figure 18 A). 
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Figure 18 The number of CD31 positive cells in the infarcted myocardium increased in the wt/wt 
BM+anti-MIF and wt/Cxcr2 BM+anti-MIF mice compared to their isotype controls 1 w after I/R (A). The 
collagen content was reduced by anti-MIF antibody treatment in all the experimental groups compared to 
their controls 1 w after I/R (B). (A, B) Hearts were isolated 1 wafter I/R and cut into 5µm sections. Serial 
sections (3 sections/mous) were stained for the content of vessels (CD31). Vessels were counted in 6 different 
fields/section expressed as vessels/µm². (*p<0.05, n=6-10, Sclae bar 25µm) (B) representative CD31 stains from 
(A). (C) Hearts were isolated 1 w after I/R and for  the evaluation of the collagen content, serial sections (10-12 
sections/mouse, 400 µm apart, up to the mitral valve) were stained with Gomori’s 1-step trichrome stain. The 
collagen content of infarcted area was determined in all sections using Diskus software (Hilgers). (D) 
representative Gomori stains from (C) 
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The collagen content in the infarcted area was reduced due to anti-MIF antibody 
treatment in all three groups (Figure 18 C). Wt/wt BM+anti-MIF mice show half 
amount of collagen as compared to the wt/wt BM mice. The reduction of collagen in 
the wt/Cxcr2 BM+anti-MIF mice was a little less than in the wt/wt BM+anti-MIF mice. 
The smallest decline in collagen between the anti-MIF treated mice and the 
corresponding controls was detected in the Cxcr2/wt BM mice. 
One week after I/R, the infarct size increased by trend because of anti-MIF antibody 
treatment in the wt/wt BM and wt/Cxcr2 BM mice as compared to their corresponding 
non-treated once. In contrast, the Cxcr2/wt BM mice illustrate the complete opposite 
trend. Here, the anti-MIF antibody treatment led to a reduction in infarction size 
(Figure 19). 
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Figure 19 Analysis of myocardial infarction size (%) one week after I/R. Hearts were isolated 1 w after I/R 
and for the evaluation of myocardial infarction size, serial sections (10-12 sections/mouse, 400 µm apart, up to 
the mitral valve) were stained with Gomori’s 1-step trichrome stain. The infarcted area was determined in all 
sections using Diskus software (Hilgers) and expressed as percentage of total left ventricular volume. 
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V. Discussion 
V.1. Angiogenic Potential of MIF and eEPCs in vitro and in vivo 
Myocardial infarction belongs to the leading causes of death world wide. Therefore 
new therapeutical strategies are urgently needed to regenerate the infarcted 
myocardium. Angiogenesis is a central physiological process in growth and 
development and has been shown to be an excellent therapeutic target for the 
treatment of cardiovascular disease. A large number of preclinical studies have been 
performed in animal models using different pro-angiogenic factors with promising 
results, leading to the believe that such new therapeutic approaches, when 
successfully translated into clinical settings, could rapidly be beneficial for millions of 
suffering patients 209. 
Unfortunately, most of the clinical trials did not achieve statistically significant 
improvements 210, 211, probably due to the improper choice of molecular targets in an 
overall context of a complex cellular environment in vivo. Moreover, our knowledge 
about the molecular events regulating blood vessel formation is far from being 
understood. 
The most important information about the underlying angiogenic mechanisms and the 
involved pro-angiogenic factors has come from epxeriments with knock-out mice and 
in the context of tumor research. Mice gene-deficient in the CXCL12 receptor CXCR4 
display profound defects in the hematopoietic and nervous systems and die 
perinatally 212. Similarly, VEGF is a critical regulator of somatic growth and is 
essential for survival in early postnatal life 127. Cxcr2-/- and Mif-/- mice display a 
relatively normal phenotype, but tumor growth is significantly impaired compared to 
wild-type littermates, mostly due to a decreased tumor microvascular density 213, 214. 
Since all these factors have proved important in neovascularization, corresponding 
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selective antagonists were broadly used to successfully control and suppress tumor 
growth. Nevertheless, it has to be kept in mind that promoting angiogensis could lead 
to enhanced tumor groth. Thus, it is crucial to precisly understand the mechanisms 
and known players involved in the process of angiogensis. 
Whereas anti-angiogenic approaches against selective targets have proven 
successful in tumor pathology, pro-angiogenic therapies as they would be envisioned 
in cardiovascular disease ought to cover multiple steps of angiogenesis and should 
consider the complex simultaneous and/or sequential interplay of involved 
angiogenic factors and chemokines. In hypoxic tissues, an up regulation of 
chemokine- and cytokine synthesis is induced leading to an enhanced angiogenesis, 
but it is necessary to investigate the behaviour of the progenitor cells under hypoxia 
and to evaluate their potential role in the different steps of regenerative angiogenesis. 
Thus, only by understanding these mechanisms, vessel formation may be 
manipulated and controlled in order to improve the function of a damaged organ. In 
the first part of my thesis, the multiple steps involved in angiogenesis were analyzed, 
focussing on pivotal established factors such as CXCL1 and 12 and VEGF and laying 
a particular focus on the emerging role of the angiogenic capacity of the cytokine 
MIF, for which potent properties as a non-cognate chemokine and EPC-derived pro-
angiogenic factor have recently been uncovered 170, 189. 
Endothelial progenitor cells have been assigned a crucial role in neo-angiogenesis 
100. However, since their discovery in 1997 103, their precise characterization has 
been debated. Endothelial progenitor cells appear to undergo different stages of 
differentiation and can therefore exhibit different characteristics. The so-called early 
EPCs, derived from circulating CD34-positive mononuclear cells, which gradually 
lose CD45 and CD31 expression and gain low-level expression of KDR and VE-
cadherin 102, exert enhanced adhesion proprieties but surprisingly fail to proliferate in 
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vitro 215. In contrast, a small EPC sub-fraction forms, the so-called late EPCs (OECs), 
which lack hematopoietic markers but have the ability to proliferate 215. Late EPC are 
characterized by an upregulation of KDR expression and a higher and longer 
sustained expression level of VE-cadherin and vWF but also by the gradually 
decrease of CD45 102. In addition to responding to angiogenic stimuli, both of these 
EPC sub-populations secrete angiogenic factors such as VEGF 216 and inflammatory 
cytokines/chemokines 217 driving neo-angiogenesis. The murine embryonic EPC cell 
line (the “eEPCs”) used in this study, expresses subsets of mesodermal as well as 
early endothelial cell markers, is able to adhere and proliferate, secretes pro-
angiogenic factors and improves neovascularisation and tissue recovery in vivo 205, 
206. 
Soon after the occurrence of an acute ischemic event, the affected tissue starts to 
undergo apoptotic and/or necrotic cell death and local vessel structures are being 
destroyed. Therefore, rapid neovascularization is essential for the survival of any 
residual and the renewed cells and for the preservation of organ function. In such 
situations, circulating EPCs, likely early EPCs, are being activated and adhere to the 
site of injury. This first step in new vessel formation is essential, but not sufficient to 
sustain the entire angiogenic process. 
Our data show that embryonic EPCs as well as the therapeutically used EPCs share 
similar properties (Figure 8). Both of them express a number of endothelial surface 
markers and receptors, and secrete angiogenic factors. eEPCs express even higher 
amounts of the endothelial cell markers CD31 and VEGFR-2 than EPCs do. We 
found a marked up-regulation of the surface expression of CXCR2 and CXCR4 on 
EPCs and eEPCs under hypoxia; of note, these two receptors are well known to be 
pivotal receptors in angiogenesis 65, 218. CXCR2 and CXCR4 are the principal 
receptors for CXCL1 and CXCL12, respectively, and have recently been found to 
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serve as potent non-cognate receptors for MIF as well 170. In the context of 
angiogenesis, increased MIF-triggered recruitment responses of monocytes and 
EPCs in a CXCR2- and CXCR4-dependent manner, respectively, are notable 167, 219. 
EPCs not only respond to ischemic triggers by migration, adhesion and 
differentiation, but also carry a battery of pro-angiogenic factors with them as cargo 
204, 206, 220. We showed that EPCs not only express the mRNA of angiogenic factors 
206 but also secrete angiogenic factors. Namely, the secretion of CXCL12, CXCL1, 
VEGF, and MIF was demonstrated, with MIF being the most prominent secreted 
factor at both early and later time points following ischemic challenge. These 
chemokines/-angiogenic factors are also secreted by hypoxically challenged 
endothelium 167. Thus, although the latter aspect was not explicitly analyzed in the 
current study, it appears that both locally produced EC- as well as EPC-derived 
CXCL12, CXCL1, VEGF, and MIF contribute to the production of these factors under 
ischemic challenge such as in myocardial infarction, where they would critically 
contribute to EPC recruitment and neo-angiogenesis. In fact, we found that CXCL12, 
CXCL1, VEGF, and MIF all promoted EPC adhesion, although by a small margin 
only. More markedly, essentially all factors promoted EPC and eEPC chemotactic 
migration and transmigration through endothelial layers in vitro, with MIF and VEGF 
being the most potent factors under hypoxic conditions. This effect nicely 
corresponded to an observed upregulation of surface CXCR2 and CXCR4 on the 
EPCs after hypoxic stimulation. Generally, hypoxia stimulation effects only were 
analyzed on eEPCs due to the low cell yields that are obtained for primary mouse 
spleen-derived EPCs. 
The angiogenic potency and EPC-activating capacity of all 4 studied factors also 
became apparent in in vitro tube formation assays in SVEC/eEPC-containing matrigel 
chambers. All factors, but again most prominently MIF and VEGF following hypoxic 
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prestimulation, promoted in vitro tube formation. Assessing in vivo vascularization 
responses by matrigel implants containing the angiogenic factors/chemokines either 
alone or in conjunction with eEPCs, then suggested that both local and recruited 
EPCs can contribute to an increase in tube formation in vivo, implying their role in 
vivo angiogenesis. Evidence for a role of local EPCs comes from the observation that 
the transplantation of eEPCs alone markedly amplifies the subsequent tube formation 
response, while external EPC recruitment in vivo, as measurable in our model, 
appears to be mostly triggered by VEGF. This notion is confirmed by earlier studies 
showing a gross beneficial effect of early-transplanted EPCs on cardiac function 221, 
while later systemic transplantation did not improve cardiac function. It may be 
speculated that after transmigration to an (ischemic) injured site, EPCs 
transdifferentiate into OECs, which in turn have the capacity to proliferate at the local 
site, therefore making a new import of angiogenic cells unnecessary.  
From all studied factors, MIF seems to play a central role in the angiogenic response 
under hypoxic conditions. It is already known, that hypoxia induces a biphasic pattern 
of MIF-release from endothelial cells: early secretion from preformed MIF stores 207, 
predictably responsible for self-maintaining adhesion and transmigration of EPCs and 
later secretion of MIF, attributable to HIF-1α-driven de novo MIF synthesis 167. This 
later MIF fraction could be responsible for the initiation of tube formation and 
differentiation towards endothelial and smooth muscle cell phenotypes. In fact, we 
surprisingly observed that MIF was the only factor able to favor a differentiation 
towards CD31-positive ECs and SMA-positive SMCs in vivo, suggesting an important 
role for MIF in the more advanced phases of angiogenesis as well as in 
collateralization. As VEGF secretion from EPCs was pronounced over a broad time 
interval, and because VEGF had strong effects on EPC adhesion and chemotaxis, 
VEGF likely also has an important role in the initiation of tube formation. 
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Analyzing all the data and translating the results to myocardial infarction, the 
following sequelae of events may be proposed (Figure 20): a local acute release of 
angiogenic chemokines such as CXCL1 and MIF from injured cardiomyocytes 222, 223 
leads to an early recruitment of EPCs which is critical for the initiation of 
angiogenesis. Once recruited, EPCs also release angiogenic chemokines and VEGF 
for a short time period, maintaining an activation circle and recruiting other cells 
involved in angiogenesis, including monocytes and SMCs 224, 225. Since EPC 
numbers in blood are limited, a “therapeutic” external application at such a time point 
could be beneficial for the following angiogenic processes. “Therapeutic” EPCs would 
then secrete MIF and VEGF, integrate into tube structures to form fully functional 
vessels. 
 
Figure 20 Schematic summarizing the proposed role of EPCs and the studied angiogenic 
factors/chemokines in neo-angiogenesis. After an injury and destruction of tissue, an inflammatory reaction is 
induced by the release of cytokines and angiogenic chemokines. These activate circulating EPCs, which 
upregulate their angiogenic chemokine receptors due to the hypoxic challenge, adhere and transmigrate to the 
site of injury. Here, together with monocytes they integrate into tube structures, and differentiate into mature 
endothelial cells (“vessel formation”). My data suggest that MIF and VEGF are critical players in the earlier 
processes. Also MIF, but surprisingly not CXCL12, are important in the later stages including fully functional 
vessel formation. 
 
My data suggest that among the four tested angiogenic factors, MIF is best able to 
assist in the completion of the angiogenic process, because it was the only factor that 
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induced the differentiation of the integrated cells towards an endothelial and smooth 
muscle cell phenotype. 
In conclusion, angiogenesis is a highly complex process, depending on several 
angiogenic factors and chemokines factors and involving multiple steps. EPCs are 
responsive recruited angiogenic cells but also important sources of the angiogenic 
factors. Furthermore, we have identified a previously unknown role for EPC-derived 
MIF in EPC recruitment and early tube formation steps, but also for EPC 
differentiation into ECs and SMCs as prominent in the later stages including 
collateralization. Our data contribute to an improved understanding of the complex 
angiogenic interplay between ECs, EPCs, and pivotal angiogenic factors and thus is 
a basis to fine-tune therapeutic tools in the treatment of cardiovascular diseases, in 
which the studied factors play an important role. 
V.2. Effect of Endogenous MIF on Neoangiogenesis in vivo via 
CXCR2 
As the results of the first part have shown, MIF was demonstrated to be a crucial 
player in EPC function and angiogenesis and the effect seems to be in part mediated 
by CXCR2. To investigate its role in angiogenesis after myocardial infarction, 
myocardial I/R was induced in irradiated wildtype mice reconstituted with wildtype or 
Cxcr2-/- bone marrow and Cxcr2-/- mice reconstituted with wildtype bone marrow. The 
mice were treated with anti-MIF antibody or isotype control and heart functions, 
infarct size as well as the inflammatory response were analyzed. 
Previously, it has been shown that MIF released by cardiomyocytes during ischemia 
reperfusion injury acts cardioprotectivly as it stimulates AMPK activation through 
CD74 177, 226. A CD74-dependent interaction between MIF and CXCR2 in 
inflammatory cellrecruitment has been reported by Bernhagen et. al 170. So far, it has 
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not been clear wether MIF activation of CXCR2 is also important in the cellular 
response to hypoxic injury besides its migratory function. Until now, it was shown that 
CXCR2 mediates both the infiltration of damaging inflammatory cells and a direct 
myocardial protective effect 227.Our data show that anti-MIF antibody treatment in the 
experimental bone marrow transplanted mice leads to marked changes in heart 
function (Figure 13, Figure 15) and infarction size (Figure 19). One day after 
myocardial I/R, anti-MIF antibody treatment led to a significantly decrased ejection 
fraction in the wt/wt BM mice and a slight decrease in the wt/Cxcr2 BM mice. But the 
Cxcr2/wt BM mice, treated with anti-MIF antibody, showed a significant increase in 
ejection fraction one day after myocardial I/R. Cardiac CXCR2, CXCR4 and CD74 
were present in the wt/wt BM and wt/Cxcr2 BM transplanted mice and MIF could act 
on cardiomyocytes via all three receptors. Whereas, Cxcr2/wt BM mice only express 
cardiac CXCR4 and CD74 but lack cardiac CXCR2. As the heart function in the wt/wt 
BM and wt/Cxcr2 BM groups decreased, one day (Figure 13) as well as one week 
(Figure 15) after I/R, it could be speculated that the cardioprotective effect of MIF 
possibly acting via CXCR2 is blocked by anti-MIF antibody treatment. This indicates 
a positive control of MIF via CXCR2 on the heart function. As CXCR2 is deleted on 
the circulating cells in the wt/Cxcr2 BM mice, it seems that the protective effect of 
MIF secreted by cardiomyocytes can prevent the heart tissue from severe functional 
loss. Also, a protective effect via cardiac CXCR2 can be considered. As Cxcr2/wt BM 
mice do not express CXCR2 on cardiomyocytes, the anti-MIF antibody treatment 
obtained a positive development in ejection fraction after one day, as well as long 
term improvements shown by increased LVDP and maximal and minimal pressure 
change. This positive functional change is possibly caused because MIF release from 
circulating cells is blocked by anti-MIF antibody treatment. This blockade additionally 
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reduced the number of pro-inflammatory cells which infiltrated the site of injury 
(Figure 16). 
Mononuclear cells infiltrating the site of inflammation release cytokines and 
chemokines which in turn further enhance the recruitment and activation of these pro-
inflammatory cells 7, 141. Studies in animal models that exibit impaired monocyte 
infiltration consistently showed a preserved heart function after experimental 
myocardial infarction induction 228, 229. Our data show a significant reduction of 
monocyte infiltration in the wt/wt BM and Cxcr2/wt BM mice whereas the wt/Cxcr2 
BM transplanted mice showed no change in monocyte content in the infarcted tissue. 
Formerly, it was shown that MIF has the ability to induce monocyte arrest through 
CXCR2 and that this activity is associated with MIF immobilization on endothelial 
cells 170. Since CXCR2 is knocked out on circulating cells in the wt/Cxcr2 mice the 
number of infiltrated monocytes is not only drastically reduced because of anti-MIF 
antibody treatment but also in the isotype group (Figure 16). Out of these data, it can 
be concluded, that cardiac MIF recruits CXCR2-expressing monocytes. 
It seems that MIF has also different effects on different monocyte subpopulations, 
recently described. Ly-6Chi or Gr-1high monocytes (known also as Gr-
1+CCR2+CX3CR1
lo) dominate the early phase and exhibit phagocytic, proteolytic, and 
inflammatory features, whereas Ly-6Clo or Gr-1low (knowing also as Gr-1-CCR2-
CX3CR1hi) monocytes promote healing via myofibroblast accumulation, 
angiogenesis, and deposition of collagen 230. Reducing inflammatory monocytes after 
myocardial infarction, but not reparatory monocytes, seems to have a beneficial 
effect on cardiac remodelling 231. Therefore we can assume that MIF controls a 
CXCR2+ subpopulation of inflammatory monocytes, which inhibition will induce an 
improved cardial remodelling and better heart function.  
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The neutrophil infiltration into the infarcted myocardial tissue was not altered in all 
three experimental groups. Not all cells targeted by MIF express CD74, the most 
prominent cell type are neutrophils 164, however, neutrophils express CXCR2. It has 
been shown that a moderate chemotactic activity of neutrophils towards MIF is 
related to an absence of CD74 on neutrophils 170. As CD74 is a MIF-binding protein, 
it was suspected that a functional MIF receptor needs to form a receptor complex 
containing both GPCR and CD74 170. The idea of a signaling complex with CXCR2 to 
mediate MIF function was confirmed. The reason for the constant number of 
neutrophils in the area of myocardial infarction could be the lack of CD74 on 
neutrophils and consequently the insufficient interaction with MIF. 
The evalutation of the neoangiogenesis in the infarcted tissue brought up suprising 
results. The functional data of the Cxcr2/wt BM anti-MIF mice showed no 
improvement in coronary flow (Figure 15). The number of capilaries was detected by 
CD31 immunohistochemical staining. Hence, reduced angiogenesis in respect to a 
decreased number of CD31 positive cells was expected. Suprisingly, this 
experimental animal group failed to show a reduced number of newly formed 
capilaries. The Cxcr2/wt BM anti-MIF mice show no significant change compared to 
their isotype control mice. One week after I/R surgery new capilaries already started 
to form and are detectable by stainings but are not functional yet and consequently 
the coronary flow did not recover and improve. It can be speculated, that at a later 
time point, the new formed capilaries and increased collateralization will further 
improve the heart function. The wt/wt BM anti-MIF mice show no change in capillary 
formation compared to their isotype control. Anti-MIF antibody treatment in the 
wt/Cxcr2 mice significantly improved angiogenesis indicating the crucial role of MIF 
via CXCR2 in angiogenesis. The anti-MIF antibody treatment led to a higher number 
of capillaries in the infarcted myocardium in the wt/wt BM mice and a significant 
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increase in the wt/Cxcr2 BM group. This may indicate that cardiac MIF in the 
presence of cardiac CXCR2 and CD74 blocks endothelial cell differentiation. 
It has been suggested, that high collagen contents in scars negatively influence the 
heart function. However, new data have shown that a higher collagen content in the 
scar after myocardial infarction can improve heart function 100. These findings 
indicate that not collagen by itself alters the function but maybe the collagen 
phenotype is responsible for the effects observed. MIF as well as monocyte 
infiltration seem to be part of this not yet clarified process. Anti-MIF antibody 
treatment led to a significant collagen reduction in all three treated groups which thus 
doesn´t seem to correlate with the functional data. The role of MIF and monocytes on 
the collagen phenotype is not yet know but it seems that some collagen subtypes 
have the potential to improve cardiac function after myocardial infarction. The 
detailed underlying mechanism of course needs to be clarified in the future. 
It has been shown that all cell types found in the myocardium, either under basal 
conditions (myocytes, fibroblasts, endothelial cells) or in response to an inflammatory 
stimulus (neutrophils and macrophages), express one or more types of MMP species 
232-234. Studies have shown that MMPs are involved in several cardiovascular disease 
processes, including coronary artery remodelling 235, for example caused by cardiac 
fibroblasts synthesis of several groups of MMPs, including collagenases 236. As we 
see a reduction in collagen content caused by anti-MIF antibody treatment in all three 
groups, the degradation of collagen by MMPs could be blocked by MIF and due to 
this the collagen content in scar formation could be regulated. 
In conclusion it can be stated that MIF and its functional receptor CXCR2 together 
are crucial players in myocardial regeneration and neoangiogenesis. This study gives 
new insights on how MIF can positively amplify neoangiogenesis by regulating pro-
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inflammatory cell-recruitment from the circulation after I/R surgery and inducing 
capillary formation. 
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VI. Summary 
 
Despite considerable current progress, cardiovascular diseases (CVD) represent the 
number one case of death world-wide. Although stem cell therapy has proved its 
substantial therapeutic potential improving angiogenesis, the underlying mechanisms 
are still under investigation. 
The first part of this study was entertained to analyze the multiple steps involved in 
angiogenesis, focusing on pivotal established factors such as CXCL1 and CXCL12 
and VEGF, and laying a particular focus on the emerging role of the angiogenic 
capacity of the cytokine/chemokine MIF, under normoxic as well as under the hypoxic 
conditions. In the second part, MIF’s pro-angiogenic potential and its functional 
receptor CXCR2 were investigated with regard to their role in improving neo-
angiogenesis or in conveying protection after myocardial I/R injury. 
Isolated mouse EPCs and murine embryonic EPCs (eEPCs) were analyzed for the 
expression and secretion of known angiogenic factors and chemokines as well as the 
components of the MIF/CXC chemokine receptor axis. In particular, the influence of 
hypoxic versus normoxic stimulation was assessed. Hypoxic stimulation induced an 
up-regulation of the surface expression of CXCR2 and CXCR4 but not CD74 on 
(e)EPCs and potently triggered the secretion of CXCL12, CXCL1, MIF, and vascular 
endothelial growth factor (VEGF). These EPC-derived factors potently stimulated the 
chemotactic and transmigration activity as well as adhesive capacity of EPCs, with 
MIF and VEGF exhibiting the most potent effects under hypoxic conditions. MIF-, 
VEGF-, CXCL12-, and CXCL1-stimulated EPCs markedly enhanced tube formation 
in vitro, with again MIF and VEGF exhibiting the strongest effect following hypoxic 
treatment. Tube formation as assessed by an in vivo implantation model utilizing 
angiogenic factor-loaded matrigel plugs was only promoted by VEGF. Co-loading of 
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plugs with eEPCs and angiogenic proteins led to enhanced tube formation by 
CXCL12 but not the other factors, whereas MIF was the only angiogenic factor able 
to induce a differentiation towards an endothelial and SMCs phenotype, the latter 
indicating collateralization capacity. Surprisingly, CXCL12, which is a main 
chemoattractant for smooth muscle progenitor cells, inhibited SMC differentiation. 
As shown in the first part of my thesis, MIF plays also a crucial role in EPC-derived 
angiogenesis. Thus, the effect of endogenous MIF on neo-angiogenesis in vivo via 
CXCR2 was investigated. For this purpose, myocardial I/R was induced in irradiated 
wild-type mice reconstituted with wildtype (wt) or Cxcr2-/- BM and Cxcr2-/- mice 
reconstituted with wt BM. The mice were treated with anti-MIF antibody or isotype 
control and heart functions, infarct size as well as the inflammatory response were 
analyzed. In conclusion, it can be stated that MIF and its functional receptor CXCR2 
together are crucial players in myocardial regeneration and neo-angiogenesis. This 
study gives new insight on how MIF can positively amplify neo-angiogenesis by 
regulating pro-inflammatory cell recruitment from the circulation after I/R injury and 
inducing capillary formation. 
Angiogenesis is a multi-step process, involving a complex interplay between the 
endothelium, pro-angiogenic factors and recruited EPCs. Here, I have identified a 
pivotal role for EPC-derived pro-angiogenic MIF, VEGF and MIF receptors in EPC 
recruitment following hypoxic challenge, EPC differentiation and subsequent tube 
and vessel formation, whereas CXCL12, a mediator of early EPC recruitment, does 
not contribute to the remodeling process. These findings have important implications 
for the devising of pro-angiogenic therapies in the treatment of CVD and point out the 
need to precisely identify the molecular players and sequence of steps in new vessel 
formation. 
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VII. Zusammenfassung 
 
In der Herz-Kreislaufforschung gab es in den letzten Jahrzehnten erhebliche 
Fortschritte. Trotzdem stehen Herz-Kreislauferkrankungen weltweit bei Todesfällen 
an vorderster Stelle. Sowohl die Stammzellentherapie als auch die Zytokin/- 
Chemokintherapie haben in den letzten Jahren ihr therapeutisches Potential unter 
Beweis gestellt. Die zugrunde liegenden Mechanismen sind jedoch bis heute nicht 
vollständig geklärt. 
Die vorliegende Forschungsarbeit gliedert sich in zwei Teilabschnitte. Im ersten Teil 
wurden die Schritte, welche an der Angiogenese beteiligt sind, untersucht. Dabei 
wurden unterschiedliche, bekannte angiogene Faktoren wie CXCL1, CXCL12 und 
VEGF sowie MIF als „neuer“ Faktor, sowohl unter normoxischen als auch 
hypoxischen Bedingungen verglichen. Im zweiten Teil wurde mit Hilfe des murinen 
Myokardinfarktmodells das pro-angiogene Zytokin/Chemokin MIF und sein 
funktioneller Rezeptor CXCR2 hinsichtlich ihres neo-angiogenen Potenzials 
untersucht. 
Isolierte Maus-EPCs und murine embryonale EPCs wurden hinsichtlich der 
Expression und Sekretion angiogener Faktoren analysiert. Hypoxische Bedingungen  
führten sowohl zur Hochregulierung von CXCR2 und CXCR4 an der Zelloberfläche 
als auch zu einer gesteigerten Sekretion von CXCL12, CXCL1 und MIF. Dies führte 
zu einer gesteigerten Adhäsion und Transmigration von eEPCs. Lokale und 
rekrutierte EPCs förderten zusätzlich die Tubulen-Bildung und verstärkten dadurch 
die Angiogenese. In der Hypoxie-induzierten Angiogenese spielt MIF eine zentrale 
Rolle, da dieses bei den Versuchen als einziger in der Lage war, EPCs in 
Glattmuskelzellen zu differenzieren. Es kann davon ausgegangen werden, dass 
VEGF insbesondere bei der Adhäsion und Chemoattraktion unverzichtbar ist. Für die 
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Tubulen-Bildung ist VEGF alleine nicht ausreichend, hier ist MIF notwendig, um die 
Angiogenese aufrecht zu erhalten, jedoch nicht die Kollateralisierung. CXCL12, 
bisher bekannt als der wichtigste Chemoattractant für Glattmuskelzellen, wies hier 
keinen großen Einfluss auf die Kollateralisierung auf. 
Im ersten Teil konnte die Wichtigkeit von MIF in Bezug auf die EPC-induzierte 
Angiogenese bereits gezeigt werden. Es wird vermutet, dass diese pro-angiogenen 
Effekte über CXCR2 vermittelt werden. Um die Rolle von MIF in der Angiogenese 
nach Myokardinfarkt zu untersuchen, wurde bei Knochenmark-transplantierten 
Mäusen eine myokardiale Ischämie/Reperfusion durchgeführt. Bestrahlte Wildtyp (wt) 
Mäuse erhielten einerseits wt-Knochenmark oder Cxcr2-/- Knochenmark und 
bestrahlte Cxcr2-/- Mäuse erhielten wt-Knochenmark. Die Hälfte der Tiere jeder 
Gruppe wurde entweder mit einem MIF-Antikörper oder einer Isotyp-Kontrolle 
behandelt. Nach der I/R-Induktion wurde die Herzfunktion, Infarktgröße und die 
entzündliche Reaktion beurteilt. Es konnte festgestellt werden, dass MIF und sein 
Rezeptor CXCR2, zusammen entscheidende Akteure in der myokardialen 
Regeneration und Angiogenese sind. MIF verstärkt die Neoangiogenese positiv 
indem es die Rekrutierung pro-inflammatorischer Zellen reguliert und die 
Gefäßneubildung induziert. 
Es kann daher gesagt werden, dass die Angiogenese einen hoch komplexen 
Prozess darstellt, welcher mehrere unverzichtbare Schritte beinhaltet. Um in Zukunft 
eine noch effizientere Therapie zu etablieren, wird es wichtig sein, diesen Ablauf und 
die involvierten Zytokine und Chemokine noch intensiver zu erforschen und beim 
Einsatz von pro-angiogenen Therapien zum wirkungsvollsten Zeitpunkt mit den 
entsprechenden Substanzen einzugreifen. 
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